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ABSTRACT 
O2 ACTIVATION AND ALLOSTERIC Zn(II) BINDING ON HIF-PROLYL 
HYDROXYLASE-2 (PHD2) 
SEPTEMBER 2013 
SERAP PEKTAS, B.S., CUMHURIYET UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by Professor Michael J. Knapp 
Oxygen homeostasis is essential to the life of aerobes, which is regulated in 
humans by Hypoxia Inducible Factor-1α (HIF-1α).  Under hypoxic conditions, HIF-1α 
transactivates over a hundred genes related angiogenesis, erythropoiesis, etc.  HIF-1α 
level and function is regulated by four HIF hydroxylase enzymes: three isoforms of 
prolyl hydroxylase domain (PHD1, PHD2 and PHD3) and factor inhibiting HIF-1α 
(FIH).  PHD2 is the focus of this research.  PHD2 is a non-heme Fe(II) 2-oxoglutarate 
dependent dioxygenase, which controls HIF-1α levels by hydroxylating two proline 
residues within the ODD domain of HIF-1α, then the hydroxylated prolines are 
recognized by pVHL, which targets HIF-1α for proteasomal degradation.  Under hypoxic 
conditions PHD2 cannot hydroxylate HIF-1α and its level rises in cells.  The aims of this 
research include understanding how PHD2 chooses its substrate, how the O2 activation 
occurs, and how certain transition metals inhibit PHD2. 
Our results revealed that electrostatics play a role in substrate selectivity of PHD2 
by provoking a change in the opening and closing rate of β2β3 loop for NODD and 
CODD substrates.  Mutational studies of second coordination sphere residues combined 
	   vii	  
with kinetic studies indicated that decarboxylation of 2OG is the slow step in the 
chemical mechanism.  The removal of a hydrogen-bond by the Thr387àAla mutation 
revealed a rate 15 times faster than WT-PHD2 by making O2 a better nucleophile.  Our 
results indicate that this hydrogen bonding is essential for proper O2 activation.   
Previous reports show that certain metals increase HIF-1α levels by inhibiting 
PHD2.  However there are conflicts about how this inhibition occurs, either through 
metal replacement from the active site or metals binding to a different site causing 
inhibition.  Our competitive and non-competitive kinetic assays showed different 
inhibition profiles.  Under competitive conditions Zn2+, Co2+, Mn2+, and Cu2+ can bind to 
the enzyme active site and lead to inhibition but under non-competitive conditions Zn2+, 
Co2+, and Mn2+ partially inhibit PHD2 suggesting that these metals cannot displace the 
Fe2+ from the active site.  XAS experiments with Zn2+ and Fe3+ indicate that Zn2+ binds to 
the surface of PHD2 in a six-coordinate manner composed of two Cys201, 208, His205, 
Tyr197 and two water ligands. 
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CHAPTER I 
OXYGEN SENSING 
1.1 Introduction 
Oxygen plays a key role in the energy production of cell.  Glycolysis produces 2 
adenosine-5’-phosphate molecules (ATP) whereas oxidative phosphorylation of glucose 
produces 28 to 34 ATP, making oxygen one of the key molecules in energy metabolism1.  
In addition to its role in energy metabolism, oxygen is also involved in other biochemical 
reactions making it essential to the life of aerobes.  Although it is important, the oxygen 
molecule can also be harmful at the same time. Up regulation of oxygen, termed 
hyperoxia, causes oxidative cellular damage.  Too low oxygen levels, known as hypoxia, 
are also dangerous to cells. Under hypoxic conditions cells cannot produce enough ATP 
and other oxygen required biochemical reactions do not occur.    
Thus, oxygen homeostasis is essential to the life of aerobes. Cells have their own 
system to adapt to changes in oxygen levels. In mammals this system known as hypoxia 
inducible factor (HIF), a transcription factor which functions as the major regulatory of 
oxygen homeostasis2–4. 
1.2 Hypoxia inducible factor (HIF) 
Hypoxia inducible factor is a transcription factor which activates the expression 
of the genes related angiogenesis, erythropoiesis, and ischemia, etc5–7.  HIF is 
heterodimer consisting of two subunits, HIF-α and HIF-β.  HIF-α is mostly localized in 
the cytoplasm and is highly dependent on oxygen levels whereas HIF-β subunit is mostly 
	   2	  
localized in the nucleus and is constitutively expressed; its level is independent of oxygen 
concentration2.  HIF-β, also known as the aryl hydrocarbon nuclear translocator (ARNT), 
is involved in transcriptional regulation of other genes.  HIF-α has three known isoforms, 
HIF-1α, HIF-2α and HIF-3α. Among these isoforms HIF-1α is the most studied.  HIF-
1α contains four domains: basic-helix-loop helix domain (bHLH) important for binding 
to the DNA, per-arnt-sim domain (PAS) important for dimerization with HIF-1β subunit, 
and the oxygen dependent degradation (ODD) and C-terminal transactivation domains 
responsible for its regulatory function (Figure 1.1)2,8.  
 Under sufficient cellular oxygen concentration, termed normoxia, HIF-1α is degraded 
and the transcription of hypoxia related genes does not occur.  HIF-1α stability is 
controlled by the HIF-prolyl hydroxylases (PHD1, PHD2, and PHD3 in humans)9,10 
which hydroxylate specific proline residues found in the N- and C-terminal O2-dependent 
degradation domains of HIF-1α: NODD (Pro402) and CODD (Pro564), leading to 
proteasomal degradation of HIF-1α11,12. 
 
Figure 1.1 Domains of HIF-1α and HIF-1β. 
1.3 HIF-α  hydroxylases  
There are four HIF hydroxylase enzymes which hydroxylate HIF-1α, three 
isoforms of HIF prolyl hydroxylase domain (PHD1, PHD2, and PHD3) and factor 
inhibiting HIF (FIH).  PHD’s and FIH follow different pathways in regulation HIF-1α 
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(Figure 1.2)13.  PHD hydroxylates two proline residues in the ODD domain of HIF-1α 
which target HIF for proteasomal degradation3,14.  On the other hand, FIH hydroxylates 
the Asn308 residue in the CTAD domain of HIF-1α15–17.  Asparagine hydroxylation of 
HIF-1α does not inhibit translocation to the nucleus, dimerization with HIF-1β subunit, 
or binding to DNA but prevents the binding of transcriptional coactivator p300.  Without 
p300 transcription does not occur15–18. 
1.4 HIF Prolyl hydroxylase (PHD2) 
 HIF prolyl-4-hydroxylase (PHD), is a non heme Fe(II), 2-oxoglutarate (2OG) 
dependent oxygenase.  It is an O2 sensor in humans and regulates the level of 
transcription factor, HIF-1α, in the cell by hydroxylating specific proline residues on 
ODD domain of HIF-1α10,19–21.  Involvement of HIF-1α in aerobic/anaerobic metabolism, 
angiogenesis, and erythropoiesis makes the PHD2 target for HIF-1α mediated disease22, 
23.  PHD has three isoforms PHD1 (HPH3, EGLN2), PHD2 (HPH2, EGLN1) and PHD3 
(HPH1, EGLN3)24,25 among these isoforms PHD2 is deemed the major O2 sensor in 
humans19,24,26, as suggested by its higher expression level than the other isoforms, thus it 
is the main focus of this research.  PHD1 is localized in nucleus, PHD2 is mostly 
localized in cystoplasm and PHD3 is distributed in both the cystoplasm and nucleus27.  
PHD1 and PHD2 can hydroxylate Pro402 and Pro564 whereas PHD3 only hydroxylates 
Pro564 but not Pro402 27 hydroxylated prolines then captured by  the von Hippel-Lindau 
tumor suppressor (pVHL), a part of E3 ubiquitin ligase which targets HIF-1α for 
protesomal degradation11,24,28,29.  Hydroxylation of one of these proline residues is 
enough for degradation11,12,30.  PHD2 N-terminal contains Myeloid Nervy and DEAF-1 
(MYND)-type zinc finger domain and C-terminal contains catalytic domain31,32.  PHD2 
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expressed as only C-terminal catalytic domain due to solubility problem of full length 
PHD2.  In order for PHD2 function it requires O2, Fe2+, 2OG, and ascorbic acid to keep 
the Fe in reduced state.  The PHD2 active site is six coordinate, with an Fe2+ cofactor 
coordinated in a common His2Asp facial triad and three aquo ligands. 
 Despite its physiological importance, questions remain about the specifics of 
PHD2. One of the questions is, what is the substrate preference of PHD2? And how does 
PHD2 choose between the CODD and NODD substrates?  This is important to 
understand in order to design effective peptide inhibitors and we addressed this question 
using substrate competition assays, electrostatics, and global hydrogen deuterium 
exchange experiments (HDX).  Another important question to answer is, how does 
substrate binding trigger O2 activation and what is the mechanism O2 activation?  This 
question remains unknown for all the HIF hydroxylases.  We studied O2 activation of 
PHD2 by making point mutations of second coordination sphere residues which are 
involved in hydrogen bonding to first coordination sphere residues.  We used steady state 
kinetic assays and kinetic solvent isotope effect experiments (KSIE) to evaluate these 
mutations.  The third question that remains to be answered is, what is the mechanism of 
metal inhibition of PHD2?  It is known that certain transition metals inhibit PHD2 but 
how do they inhibit the enzyme is unknown.  The first possibility is that these metals 
inhibit PHD2 by replacing the Fe2+ cofactor within the active site or that these metals 
inhibit PHD2 by binding to an allosteric site on the enzyme rather than the active site.  
We investigated the mechanism of metal inhibition by performing metal competition 
assays and through X-ray absorption spectroscopy. 
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Figure 1.2 Hypoxia pathway. 
1.5 Proposed chemical mechanism for HIF hydroxylases 
HIF hydroxylases have a six coordinate active site.  Within the active site, Fe2+ is 
coordinated with 2His1Asp facial triad and three water ligands.  A consensus chemical 
mechanism has been proposed for this family of enzymes in which the activation of 
oxygen leads to decarboxylation of 2OG and the hydroxylation of the substrate (Figure 
1.3)33,34.  According to the consensus mechanism, binding of 2OG displaces two aquo 
ligands from the active site33,34. When substrate binds an additional aquo ligand is 
released and the coordination geometry of Fe(II) changes from six to five coordinate, 
creating a binding site for O235. Upon binding of O2, activated oxygen decarboxylates 
2OG, forming a Fe(IV)-oxo intermediate. This Fe(IV)-oxo intermediate hydroxylates the 
substrate36,37.  
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Scheme 1.1 The consensus chemical mechanism for 2OG oxygenases. 
1.6 Materials and methods 
1.6.1 PHD2 mutations 
Mutation primers were designed using the Quick change primer design program 
of Stratagene.  Secondary structures (i.e. hairpins) were checked using Integrated DNA 
technologies (IDT).  Primers were purchased with purity of  >85% (using HPLC) through 
IDT.  PCR reactions were prepared as shown in table 1.1 then the PCR performed using 
the program settings in table 1.2.    After the PCR reactions, the 10 µL of each samples 
mixed with 2 µL 6X loading dye then run on an agarose gel with 100 volt power.  PCR 
reactions, which had products were transformed into XL1-Blue cells and DNA 
sequencing was performed at GeneWiz.  Sequencing primers used were #29 forward 5’-
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GTACCTGGGTTACACGGACCTAC-3’ and #35 reverse 5’ – 
CTCCGCTATCGCTACGTGACTG – 3’. 
 
Figure 1.3 pGEX-4T-1 vector plasmid map with PHD2, glutathione S-transferase (GST) 
tag and thrombin cleavage site (GE Healthcare). 
Table 1.1 PCR reaction mixtures. 
Reagent Stock concentration Volume used Final amount 
ddH2O  84 µL  
10X reaction buffer  10 µL  
dNTP  1 µL  
MgSO4 100 mM 1 µL 1 mM 
Primer (Sense) 125 ng/µL 1 µL 125 ng 
Primer (Anti-sense) 125 ng/µL 1 µL 125 ng 
pGEX-4T 100 ng/µL 1µL 100 ng 
Vent polymerase  1 µL  
 
989 AvaI (1)
989 XhoI (1)
970 NaeI (1)
970 NgoMIV (1)
936 SacII (1)
930 BamHI (1)
Thrombin 918..938
682 SwaI (1)
647 XmnI (1)
GST 258..938
463 MscI (1)
289 DraII (1)
164 SspI (1)
1294 NcoI (1)
PHD2 939..1682
1423 AccI (1)
1423 BstZ17I (1)
1537 NdeI (1)
1671 AatII (1)
1671 ZraI (1)
1918 PstI (1)
2159 Eam1105I (1)
3668 MluI (1)
3345 BstAPI (1)
3244 PflMI (1)
2944 DrdI (1)
2638 AlwNI (1)
3849 BstEII (1)
3875 ApaI (1)
3875 Bsp120I (1)
4116 EcoRV (1)
4172 HpaI (1)
4307 SfoI (1)
Vector Map
4969 bp
4307 BbeI (1)
4307 KasI (1)
4307 NarI (1)
4760 Bsu36I (1)
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Table 1.2 PCR program settings. 
Step Temperature (OC) Time 
Denaturing 95 50 seconds 
Denaturing 95 50 seconds 
Annealing 62-65 50 second 
Extension 72 7 minutes 
Extension 72 7 minutes 
Store 4  
Steps shown in bold represents 16 cycles performed. 
1.6.1.1 Reagents and protocol 
50X TAE buffer (agarose gel running buffer) (1 L) 
 Tris base 242 g  2 M 
Acetic acid 57.1 mL 
Na2EDTA 37.2 g  2 M 
Volume adjucted to 1 L with ddH2O. 
 
10 % agarose gel 
 Agarose 1 g 
 TAE buffer 100 mL 
Heated inside the microwave until completely dissolved. 
1.6.2 WT-PHD2 and its variants purification 
The cell paste was thawed and suspended in lysis buffer with the ratio of 2 mL 
lysis buffer per gram of cell paste.  The cell was treated by ultra-sonication until the 
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solution became homogenous. After sonication, DNAse was added with the ratio of 0.5 
µl DNAse per mL of cell lysate and the solution was incubated for 30 minutes at 4 oC.  
Next, the cell lysate was centrifuged for 45 minutes at 12500 rpm to remove cell debris.  
The supernatant was then dialyzed with 1X PBS pH 7.40 at 4 oC overnight to equilibrate 
with the buffer and pH. 
 
The cell lysate was filtered with 0.45 mm sterile filter to remove any particles.  
GSTrap column buffer was adjusted with 1X PBS pH 7.4 buffer then cell lysate was 
loaded to the column with 1 mL/min flow rate.  After loading the cell lysate to the 
GSTrap column, the column was washed with 1X PBS pH 7.4 to remove unbound 
proteins.  Then GST-PHD2 eluted off the column by elution buffer.  The eluted GST-
PHD2 was buffer exchanged by dialysis overnight in 1X PBS pH 7.4 at 4 oC for thrombin 
cleavage.  Following buffer exchange, eluted GST-PHD2 was treated with restriction 
grade thrombin to cleave the GST-tag with the ratio of 0.5 unit thrombin per mg of GST-
PHD2 for 16 hours at 4 oC.  After 16 hours of thrombin treatment, thrombin was removed 
by HiTrap-Benzamidine column followed by GST-tag removal by GSTrap column.  
Purity of protein was monitored using 10 % SDS page and mass spectrometry was used 
to determine the mass of the PHD and its mutants.  Later, pure PHD2 was treated with 50 
mM EDTA for overnight to remove any metal residue at 4 oC.  Then pure PHD2 was 
buffer exchanged with 50 mM HEPES pH 7.5 and stored at -20 oC. 
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Figure 1.4 SDS page showing the purity of purified PHD2. 
1.6.2.1 Reagent protocol 
10X PBS buffer preparation (1 L) 
 80 g NaCl 
 2 g KCl 
 14.4 g Na2HPO4 
 2.4 g KH2PO4 
Dissolve in ddH2O and adjust the volume to 1 L.  Autoclave and pH adjusted to 
7.4. 
 
Lysis buffer 
 3.1 mg DTT 
 4.8 mg AEBSF 
 6 mg lysozyme 
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 50 mM EDTA 
 0.1 % TritonX 
Dissolve in 1XPBS and adjust the pH to 8.00 by adding 1M NaOH. 
Adjust the volume to 20 mL. 
 
Elution buffer 
 153.6 mg reduced gluthadione 
 0.5 mL Tris (1M stock) 
Dissolve in ddH2O and adjust the pH to 8.00 by adding 1M NaOH. 
Adjust the volume to 50 mL. 
 
50 mM HEPES 
 2.38 mg HEPES 
 Dissolve in ddH2O and adjust the pH to 7.50 by adding 1M NaOH. 
 Adjust the volume to 20 mL with ddH2O. 
 
10 % SDS  
 10 g SDS is dissolved in water and adjust final volume to 100 mL. 
Keep in room temperature. 
 
10 % ammonium persulfate (APS) 
 1 g ammonium persulfate is dissolved in ddH2O. 
Final volume is 10 ml. 
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Separate into 250 µL/tube.  
Freeze in -20°C. 
 
5 % stacking gel for SDS page 
 0.5 M Tris pH6.8      0.5 mL 
33.3% Acrylamide/Bis-acrylamide (19:1)   0.6 mL 
10% SDS      50 µL 
TEMED       5 µL 
10% APS      50 µL 
ddH2O       2.75 mL 
 
10 % separation gel for SDS page 
 1.5 M Tris pH8.8      2.5 mL 
33.3% Acrylamide/Bis-acrylamide(19:1)   3 mL 
10% SDS      100 µL 
TEMED       5 µL 
10% APS      100µL 
ddH2O       4.3 mL 
 
1.6.3 The extinction coefficient of PHD2 
The extinction coefficient of PHD2 was determined based on he method provided 
by von Hippel et al.  In sample preparation, 20 µM PHD2 was in either 6 M GuHCl or 50 
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mM HEPES pH 7.50 buffers.  Absorbance at 280 nm was recorded by UV-Vis 
spectrometer and εPHD2 determined using following equations. 
 A = εlc      (1a) 
 c = A/εl     (1b) 
 c(native) = c(6M GuHCl)    (1c) 
 A(native) / ε(native) = A(6M GuHCl) / ε(6M GuHCl) (1d) 
 ε(native) = ε(6M GuHCl) × A(native) / A(6M GuHCl) (1e) 
 
The ε(6M GuHCl) is calculated by using table 1.1 and the following equation. 
ε(6M GuHCl) = aε(Trp) + bε(Tyr) + cε(Cys) (1f) 
The a, b, and c letters represent the number of tryptophan, tyrosine, and cysteine residues, 
respectively.  The extinction coefficient of these residues was provided by von Hippel et 
al. and shown on table 1.1. 
 
Table	  1.2	  The	  extinction	  coefficients	  of	  fluorescent	  residues.	  
Residue  ε280 nm  
Tryptophan a 5690 
Tyrosine b 1280 
Cysteine c 120 
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1.6.4 Determination of the molecular weight of purified WT-PHD2 and its mutants 
by mass spectrometer 
Molecular weights of WT-PHD2 and its variants were determined by using 
QStar-TOF mass spectrometer.  20 µL of 5 µM of each protein sample was run through a 
C18 HPLC column with a 10 minute gradient before being injected into QStar-TOF mass 
spectrometer.  Then the molecular weight was predicted using Analyst QS 1.1 software. 
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Figure 1.5 Masses of WT-PHD2, Thr387àAla, Thr387àAsn, Cys201àAla, Asp315àAla, 
Asp315àGlu and Thr325àAla by QSTAR-TOF mass spectrometer. 
 
Table 1.3 HPLC gradient protocol. 
Time (min) %B 
0 5 
1 5 
2 5 
3 95 
5 5 
10 5 
 
1.6.5 Purification of NODD peptide 
The 20 residue NODD (DALTLLAP402AAGDTIISLDYG) substrate peptide 
containing the target Pro402 residue was obtained from EZbiolabs as desalted powder.  
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Desalted lyophilized NODD was dissolved in 20 % acetonitrile water solution.  Then the 
sample was injected into a HPLC column (Higgins Analytical) and purified using the 
gradient on table 3.  NODD came off of the column between 15-20 minutes of gradient.  
Collected NODD sample from HPLC column, lyophilized, and reloaded onto the HPLC 
column. This procedure was repeated three times to ensure the purity of peptide.  Final 
sample was lyophilized and stored in -20 oC. 
 
Table 1.4 HPLC gradient for NODD purification. 
Time (min) %B 
0 30 
5 31 
23 37 
25 95 
30 95 
32 30 
37 30 
 
The extinction coefficient of NODD determined as 1280 M-1cm-1 using the equation 1.  
The concentration of NODD was measured based on the absorbance at 280 nm on UV-
VIS spectrometer. 
1.6.6 Mass of purified NODD determined by MALDI 
In order to determine the mass of NODD peptide MALDI was used.  Purified 
NODD sample was added to saturated α-cyano-4-hydroxycinnamic acid solution, 
	   19	  
dissolved in 75 % acetonitrile 0.2 % trifluoro acetic acid.  Then the sample was spotted 
onto a MALDI target plate and analyzed. 
 
Figure 1.6 Mass of purified NODD determined by MALDI. 
1.6.7 Initial rate determination of PHD2 and its variants 
 Initial rates were measured using saturating concentrations of Fe(II) (10 µM), 2OG 
(100 µM), ascorbic acid (1 mM), PHD2 or its variants (1-5 µM), and ODD (1- 50 µM) in 
50 mM HEPES at 37 oC.  Reaction mixture including ascorbic acid, Fe(II), 2OG, and 
PHD2 was incubated for 3 minutes then the reactions were initiated by adding the 
substrate ODD.  Initial rates were obtained by quenching the reactions at varied time 
points in MALDI matrix solution.  Then the samples were spotted onto a MALDI target 
plate an analyzed (Figure 1.7). 
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Figure 1.7 MALDI spectrum showing the formation of hydroxylated peptide by time.  
Black spectrum is CODD peptide at 30 seconds of the reaction.  Gray spectrum is CODD 
peptide at 2.5 minutes of the reaction. 	  
 
Figure 1.8 The initial rate of CODD hydroxylation. 
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1.6.8 Global hydrogen deuterium exchange experiments 
Global HDX experiments were measured with an ABI QStar-XL mass 
spectrometer. PHD2 (50 µM) was pre-incubated in 10 mM NH4OAc at pH 7.00 on ice 
with the cofactor and substrates as indicated: MnSO4 (200 µM), 2OG (1.0 mM), and 
CODD or NODD (0 - 500 µM).  Mn2+ was used as a structural mimic of Fe2+ in order to 
avoid spurious oxidation.  The HDX reactions were initiated by diluting 3 µL of PHD2 
samples with 27 µL 10 mM NH4OAc (in D2O) pD 7.00 at 25 oC, with aliquots quenched 
by injecting onto an HPLC loop at various time points from 15 second to 60 minutes.  
Solution pD was determined by adding 0.4 to the pH meter reading (pD = pHmeter + 0.4).  
HDX aliquots (20 µL) were injected and buffer exchanged using a C18 HPLC column 
with a 0.1 % formic acid (pH 2.5) mobile phase.  The HPLC column, injection loop, and 
mobile phases were kept in an ice bath to minimize amide back exchange during sample 
workup.  PHD2 was eluted with a 10 minute gradient, (H2O / CH3CN, 0.1% formic acid), 
and was directly sprayed into an ABI QStar-XL for determination of global deuterium 
incorporation level.  Data was analyzed using Bioanalyst software.   
During analysis of HDX samples some amide hydrogens can back exchange with 
the HPLC solvent, leading to an apparent loss of deuteration.  In order to correct for back 
exchange occurring during the LC steps, the deuterium content of PHD2 at each quench 
point was corrected through comparison with the mass of a non-deuterated sample (m0) 
and the mass of a fully deuterated PHD2 sample (m100).  The fully deuterated protein was 
prepared by incubation in D2O for a day at 37.0 oC followed by 10 minutes at 70 oC.  The 
number of exchangeable backbone amides (D) was then calculated by subtracting the 
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number of Pro residues (12) and the N-terminus from of the total number of 
exchangeable amides on PHD2 (N = 236). 
D = N × (mobs – m0)/(m100 – m0)  
 
 
Figure 1.9 Determination of deuterium incorporation to PHD2 with time.  QStarXL is 
used to determine mass change in PHD2 with time.  Black mass spectrum is apo PHD2 (5 
µM) at time 0 and gray mass spectrum is apo PHD2 (5 µM) at 60 minutes.  Mass of 
PHD2 was determined by Analyst QS 1.1 software and predicted charge states were 
shown. 	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Figure 1.10 Closer view of the mass spectrum in figure 1.9, showing the mass change 
due to deuterium incorporation to the protein for +34 and +33 charge state at time 0 
(black) and 60 minutes (gray).  X is impurities.  	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CHAPTER II 
SUBSTRATE SELECTIVITY OF PHD2 
2.1 Introduction 
Oxygen homeostasis in humans and other metazoans is transcriptionally regulated 
by the hypoxia inducible factor-1α (HIF-1α)1,2, which governs cellular responses to 
hypoxia, such as the balance of aerobic/anaerobic metabolism, angiogenesis, and 
erythropoiesis.   HIF-1α stability is controlled by the HIF-prolyl hydroxylases (PHD1, 
PHD2 and PHD3 in humans)3,4, which hydroxylate specific Pro residues found in the N- 
and C-terminal O2-dependent degradation domains of HIF-1α: NODD (Pro402) and the 
CODD (Pro564), leading to proteasomal degradation of HIF-1α5,6.  Hydroxylation of 
either Pro402 or Pro564 is sufficient to for HIF-1a to bind tightly to pVHL5,6, leading to 
proteasomal degradation7.  A key question in this field is substrate selectivity of PHD 
isoforms toward the ODD domains, as this determines the stability of HIF-1α. As PHD2 
is thought to be the primary O2-sensor under normoxic conditions8, and it is the only 
PHD isoform with a high-yield recombinant expression, detailed enzymological studies 
of PHD2 are important both to understand the chemical mechanisms of prolyl 
hydroxylation, as well as to identify the basis for substrate selectivity in PHD2 and 
related enzymes.   
PHD2 is a non-heme Fe(II), 2-oxoglutarate (2OG)-dependent oxygenase that is 
thought to follow the consensus mechanism for related oxygenases (Scheme 2.1)9–11.  In 
this ordered mechanism, substrates bind in the order 2OG, primary substrate (ODD), then 
O2.  Binding of the primary substrate triggers O2 binding by inducing the formation of a 
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5-coordinate Fe(II) cofactor10,12, and associated changes to local contacts within the 
active site.  Oxidative decarboxylation leads to formation of a putative Fe(IV)O 
intermediate13–15 (Scheme 2.1), which effects hydroxylation of the target Pro residue 
(CODD, Pro564; NODD, Pro402) to complete the cycle.  As the half-reactions are 
sequential, oxidative decarboxylation that is uncoupled from hydroxylation can occur16, 
leading to excessive consumption of 2OG in some cases.   
 
Scheme 2.1 Consensus mechanism and ODD sequences.   
Cell-based assays have shown that the PHD isoforms exhibit differential 
selectivity toward the ODD domains, with PHD2 reacting more rapidly with CODD than 
NODD in HIF-1α constructs17.  Immunoblotting showed CODD hydroxylation prior to 
NODD hydroxylation in cell-based assays suggesting some level of synergy between the 
two sites18, however binding assays of very long ODD constructs revealed that CODD 
bound to purified PHD2 with roughly ten-fold increased affinity relative to NODD19, 
suggesting that intrinsic binding affinity may explain the apparent hydroxylation order.  
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Due to the complicated relationship between local and extended ODD sequences on 
PHD2 activity18,20, we used short peptides (~20 residues) containing the local ODD 
sequences to test for local effects on the substrate selectivity of PHD2.   
There are conflicting reports as to the substrate selectivity of PHD2 toward the 
two ODD domains, as the reactions of PHD2 with NODD and CODD have been reported 
with widely varying rates (kcat/KM) and Michaelis constants (KM).  Early reports based on 
2OG consumption assays were widely divergent in terms of reported KM values.  Assays 
using PHD2 within crude cell lysates indicated a strong preference for CODD (KM(NODD) 
= 130 µM, KM(CODD) = 7 µM)21; whereas assays using purified PHD2 indicated essentially 
equivalent substrate preferences: (KM(NODD) = 44 µM, KM(CODD) = 37 µM)19.  In contrast, 
O2-consumption assays using purified PHD2 indicated a marked preference for CODD 
(KM(NODD) = 24 µM, KM(CODD) = 2 µM), differing from the results  of the 2OG assay22.  
Although the biochemical data indicate that CODD is preferred , the wide variation in KM 
presents a challenge to understanding how the rates relate to substrate binding for PHD2.   
The large variation in reported values for the Michaelis constants, with KM(NODD) 
values ranging from 20 – 50 mM and KM(CODD) values ranging from 1 – 30 mM17,19,23, is 
largely a reflection of three factors that introduce variation into the kinetic data, two of 
which are common to the broad class of 2OG oxygenases.  First is the inherent difficulty 
of measuring turnover for the 2OG oxygenases, due to the relatively slow rate of turnover 
and the absence of chromophoric substrates.  This has lead to a reliance in many reports 
on the decarboxylation assay that measures the release of 14CO2 from [1-14C]2OG.  
Second is the tendency for 2OG oxygenases to uncouple oxidative and reductive half-
reactions, leading to decarboxylation without substrate hydroxylation24–26.  This in turn 
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greatly impacts assays that rely on the rate of CO2 liberation or O2 consumption, and 
certainly leads to over-estimation of turnover rates.  Third is the pKA = 7.2 of the Fe2+-
OH2 group in (Fe+2OG)PHD223, leading to a significant decrease in activity as pH is 
increased above the pKa27.  Based on these divergent Michaelis constants, and the 
potential for uncoupled oxidative decarboxylation to inflate the observed rates, we felt 
that the substrate preference and rates could be better defined by directly measuring the 
formation of hydroxylated product (ODDOH) using MALDI-TOF28,29. 
It appears that PHD2 may discriminate NODD from CODD due to a combination 
of electrostatics and a conformational change of the b2b3 loop (Fig. 1).  Closure of the 
b2b3 loop is essential for tight ODD binding, as shown by the crystal structure of 
CODD/(Mn+NOG)PHD230, and activity assays with chimeric PHD enzymes7.  Sequence 
comparison shows that CODD contains six acidic residues, compared to three for NODD 
(Scheme 1), suggesting that electrostatics may be the origin of differential binding – this 
is supported by the sequence preference of PHD2 (–AP(Y/F)(I/L)X4(D/E)–) obtained 
from yeast two-hybrid binding assays31.  Further, protease susceptibility assays showed 
that CODD/PHD2 was greatly stabilized relative to NODD/PHD2, both in terms of the 
length of time required for proteolysis as well as in the proteolytic site on the b2b3 loop 
stabilized by ODD binding32.   
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Figure 2.1 Structure of (Mn+NOG)PHD2 bound to CODD [30] showing the β2β3 loop 
(red) and CODD (cyan) PDB IDs:3HQR and 2G19.   
 
The contribution of ODD/PHD2 binding to the catalytic efficiency of PHD2 
(kcat/KM) is not fully defined, despite its importance to O2 sensing.  Catalytic efficiency 
dictates the rate constant under conditions of low substrate concentration, and provides 
insight into the basis for discriminating NODD from CODD.  Microscopic steps 
contributing to kcat/KM include those steps between the diffusional collision with ODD 
through the first irreversible step – as a consequence, weaker binding of NODD relative 
to CODD could constitute the entire basis for substrate selectivity of PHD2.  
Furthermore, binding equilibria can contribute to overall rate-limitation, making 
understanding the binding ODD/PHD2 process a key factor in understanding the 
chemistry of O2-sensing.   
Here we tested the origin of substrate selectivity of PHD2 by direct competition 
assays, increased ionic strength, and global protein flexibility for PHD2 upon binding 
ODD.  Our results indicate that PHD2 prefers CODD by 20-fold over NODD, and that 
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electrostatics accounts for approximately 15% of this effect.  We also performed global 
hydrogen deuterium exchange experiments (HDX) with the aim of monitoring possible 
different structural changes upon binding of each substrate to the enzyme.  Our global 
HDX data reveals that binding of Fe(II) and 2OG to the enzyme active site stabilizes the 
overall enzyme structure as reported previously by proteolysis studies32, however we 
noted a crucial difference from that earlier report.  At saturating concentrations of 
substrate, CODD and NODD gave indistinguishable HDX profiles, which strongly 
suggests that both substrates stabilize the b2b3 loop to the same extent.  This implicates 
loop closure as the dominant contributor to selectivity in PHD2.   
2.2 Experimental Procedures 
2.2.1 Materials 
All chemicals were purchased from commercial vendors, and used without 
purification with the exception of NODD.  The sequences of the peptide substrates were 
derived from the native HIF-1α395-414 (NODD) and HIF-1α556-574 (CODD) sequences.  
The sequence of the NODD peptide used in this work was 
DALTLLAP402AAGDTIISLDYG and the CODD peptide was 
DLDLEALAP564YIPADDDFQL. The underlined residues were changed from the native 
sequences as follows: NODD (F413Y), CODD (M561A, M568A).  The NODD peptide 
(desalted) was purchased from EzBiolab (Carmel, IN, USA) and purified by C18 column 
reversed phase-HPLC using an H2O/CH3CN gradient (5 - 95% CH3CN, 0.1% TFA), 
whereas the CODD peptide (99 % purity) was purchased from GL Biochem LTD 
(Shanghai). 
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2.2.2 Protein expression and purification 
Recombinant human PHD2 (corresponding to residues 178-426 of the full-length 
PHD2 sequence) was expressed and purified as previously reported23.  PHD2 was 
expressed with an N-terminal GST tag (GST-PHD2) in E. coli BL21(DE3) cells using a 
pGEX-4T-1 vector (Stratagene).  The GST-PHD2 fusion was purified using an affinity 
column (GSTrap, GE Bioscience), then the GST tag was removed by incubating GST-
PHD2 with restriction grade thrombin for 16 hours at 4 oC.  Thrombin was removed by a 
Hitrap Benzamidine column (GE Bioscience), and un-cleaved GST-PHD2 and GST was 
removed with a GSTrap column.  PHD2 was treated with 50 mM EDTA then buffer 
exchanged into 50 mM HEPES pH 7.00 and stored at - 20.0 oC.  PHD2 purity was 
checked by SDS-PAGE, and the molecular weight determined using a QStar-XL hybrid 
quadrupole-TOF mass spectrometer (Applied Biosystems).   
2.2.3 Steady-state kinetic assays 
All activity assays were performed with saturating concentrations of 2OG (100 
µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), and 1 µM PHD2 in 50 mM HEPES 
pH 7.00 at 37.0 oC.  Reactions were quenched at different time points with 2:1 ratio of 
acetonitrile and 0.2 % trifluoroacetic acid saturated with 4-α-cyano hydroxycinnamic 
acid.  Samples were then spotted onto a target plate and analyzed by a Bruker Daltonics 
Omniflex MALDI-TOF mass spectrometer.  Initial rates (v0) were obtained from the 
temporal change in mol fraction of hydroxylated ODDOH (cODDOH), as v0 = [ODD]0 
cODDOH /t.   
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2.2.4 Global hydrogen deuterium exchange (HDX) kinetics of PHD2 
Global HDX experiments were measured with an ABI QStar-XL mass 
spectrometer. PHD2 (50 µM) was pre-incubated in 10 mM NH4OAc at pH 7.00 on ice 
with the cofactor and substrates as indicated: MnSO4 (200 µM), 2OG (1.0 mM), and 
CODD or NODD (0 - 500 µM).  Mn2+ was used as a structural mimic of Fe2+ in order to 
avoid spurious oxidation.  The HDX reactions were initiated by diluting 3 µL of PHD2 
samples with 27 µL 10 mM NH4OAc (in D2O) pD 7.00 at 25 oC, with aliquots quenched 
by injecting onto an HPLC loop at various time points from 15 second to 60 minutes.  
Solution pD was determined by adding 0.4 to the pH meter reading (pD = pHmeter + 0.4).  
HDX aliquots (20 µL) were injected and buffer exchanged using a C18 HPLC column 
with a 0.1 % formic acid (pH 2.5) mobile phase.  The HPLC column, injection loop, and 
mobile phases were kept in an ice bath to minimize amide back exchange during sample 
workup.  PHD2 was eluted with a 10 minute gradient, (H2O / CH3CN, 0.1% formic acid), 
and was directly sprayed into an ABI QStar-XL for determination of global deuterium 
incorporation level.  Data was analyzed using the Bioanalyst software.   
During analysis of HDX samples some amide hydrogens can back exchange with 
the HPLC solvent, leading to an apparent loss of deuteration.  In order to correct for back 
exchange occurring during the LC steps, the deuterium content of PHD2 at each quench 
point was corrected through comparison with the mass of a non-deuterated sample (m0) 
and the mass of a fully deuterated PHD2 sample (m100).  The fully deuterated protein was 
prepared by incubation in D2O for a day at 37.0 oC followed by 10 minutes at 70 oC.  The 
number of exchangeable backbone amides (D) was then calculated by subtracting the 
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number of Pro residues (12) and the N-terminus from of the total number of 
exchangeable amides on PHD2 (N = 236). 
D = N × (mobs – m0)/(m100 – m0)  
2.3 Results 
2.3.1 PHD2 shows a preference for CODD over NODD in the presence of both 
substrates   
PHD2 hydroxylates Pro402(NODD) and Pro564(CODD) of HIF-1α, however, 
reports conflict as to the relative substrate preference.  Some reports indicated that both 
Pro residues were hydroxylated at a similar rate, whereas other reports suggested that 
CODD was hydroxylated at a faster rate than NODD.  In order to determine the substrate 
selectivity of PHD2 activity assays were performed under competitive conditions in the 
presence of 20 µM total substrate, but with a varying ratio of NODD:CODD.  As we 
directly monitored hydroxylation via MALDI, both CODD and NODD could be 
measured simultaneously.  The initial rates for hydroxylation of both ODDs were plotted 
as a function of varied mole fraction of NODD (Figure 2.1).  As χNODD was increased, the 
initial rate for CODD hydroxylation decreased from 1.3 min-1 to 0.8 min-1; conversely, 
the initial rate for NODD hydroxylation increased from 0.04 min-1 to 0.6 min-1.  This data 
shows that PHD2 preferentially hydroxylated CODD in the presence of NODD even at 
elevated mole fraction of NODD (Figure 2.1). 
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Figure 2.2 Substrate selectivity of PHD2 under competitive condition. PHD2 (1 µM), 
2OG (100 µM), ODD (2-18 µM; 20 mM total), (NH4)2Fe(SO4)2  (10 µM) and ascorbic 
acid (1 mM) in 50 mM HEPES pH 7.00 at 37 oC.  (CODD (o), NODD (●)). 
 
2.3.2 Columbic forces are essential in substrate preference of PHD2 
 Crystallography showed the ODD-binding surface of PHD2 contained several 
basic residues whereas the ODD substrates contain acidic residues flanking the LXXLAP 
motif suggesting that electrostatics may be important in binding substrates to PHD2. In 
order to test the role of electrostatics in PHD2 substrate recognition, activity assays were 
performed in the presence of varied NaCl concentration.  The initial rates of PHD2 were 
measured as a function of varying ODD concentration in the presence and in the absence 
of 100 mM NaCl, then the rate constants kcat and kcat/KM were determined by fitting the 
data to the Michaelis-Menten equation (Table 2.1). 
  In the absence of NaCl, the kcat/KM value for CODD (1.0 µM-1min-1) was 25 fold 
higher than kcat/KM for NODD (0.04 µM-1min-1) showing that PHD2 was more reactive 
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toward CODD than NODD (Figure 2.3 and Table 2.1).  The addition of 100 mM NaCl 
did not alter the kcat/KM value of NODD (0.05 µM-1min-1) but decreased the kcat/KM for 
CODD (0.3 µM-1min-1), indicating that attractive columbics were operative in 
CODD/PHD2 binding, but not in NODD/PHD2 binding.  
 
Figure 2.3 The effect of 100 mM NaCl on the kinetics of ODD hydroxylation by PHD2. 
PHD2 was incubated with saturating 2OG (100 µM), (NH4)2Fe(SO4)2 (10 µM), and 
ascorbic acid (1 mM), but varied ODD (0 – 50 mM) in 50 mM HEPES pH 7.00 at 37.0 
oC.  CODD, (o) no NaCl added and (●) 100 mM NaCl added.  NODD, (Δ) no NaCl 
added and (▲) 100 mM NaCl added.   	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   38	  
	  	  
Table 2.1 Steady state kinetic constants for PHD2 using CODD or NODD. 
Substrate peptide  kcat (min-1)       kcat/KM (µM-1min-1) KM (µM) 
CODD (0 mM NaCl)  1.13 ± 0.05        1.01 ± 0.11  1.04 ± 0.30           
CODD (+ 100 mM NaCl) 1.18 ± 0.12        0.29 ± 0.06  4.15 ± 1.21          
NODD (0 NaCl)  0.61 ± 0.06        0.04 ± 0.01  13.53 ± 2.61  
NODD (+ 100 mM NaCl) 0.62 ± 0.04        0.05 ± 0.01  11.23 ± 2.37     
Fixed concentrations of 2OG (100 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid 
(1 mM), and ambient O2 (217 mM), but varied ODD (0 – 50 mM) in 50 mM HEPES pH 
7.00 at 37.0 oC  
    
2.3.3 NODD and CODD bind equivalently to PHD2 
 Global amide HDX was used to test solvent protection of PHD2 upon binding 
NODD and CODD.  Apo PHD2 (no added substrate or cofator) and (Mn+2OG)PHD2 
were analyzed as reference states, in which Mn(II) was used as a isosteric replacement 
for Fe(II).  Solvent protection of NODD/(Mn+2OG)PHD2 and CODD/(Mn+2OG)PHD2 
was measured under conditions of both low (20 mM) and high (50 mM) ODD 
concentrations to observe the effects of the ODD/PHD2 binding equilibrium.  Amide 
HDX timecourses (Figure 2.4) for PHD2 in different cofactor/substrate bound states were 
fitted by binning the amides into three pools (An) based on average exchange rates: fast 
(kfast = 20 min-1), intermediate (kmed = 1 min-1), slow (kslow = 0.05 min-1); the remaining 
amides were inaccessible to D2O solvent.   
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Figure 2.4 Global amide HDX kinetics of PHD2. (■) PHD2 (5 µM) in 10 mM NH4OAc 
pH 7.0, (○) PHD2 (5 µM), MnSO4 (20 µM), and 2OG (100 µM) (●) PHD2 (5 µM), 
MnSO4 (20 µM) 2OG (100 µM), and NODD (50 µM), (▲) PHD2 (5 µM), MnSO4 (20 
µM), 2OG (100 µM), and CODD (50 µM). Inset: low concentration conditions, [NODD] 
or [CODD] = 20 mM.   
 
Amide exchange occurs from solvent-exposed amides, which are those located in 
transiently unfolded or unstructured regions of the protein.  Solvent-protected amides are 
those that are either buried within a tightly structured core of the protein, or else are 
located at a macromolecular binding surface.  The key pool for interpreting the PHD2 
conformational change are the inaccessible amides (Afrozen), as these are either buried in 
the folded core of the PHD2, or protected from solvent by ODD binding.   
Solvent protection for PHD2 increased upon cofactor binding, as seen comparing 
(Mn+2OG)PHD2 to apo PHD2.  The frozen amide population increased from Afrozen =  26 
in Apo PHD2 to Afrozen = 59 in (Mn+2OG)PHD2, indicating that the core of the PHD2 
had become more tightly structured upon binding cofactor (Table 2.2).  This is likely due 
to the stabilizing effect of metal and 2OG binding, which connects several strands of the 
b-barre30,33.   
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Binding of NODD or CODD under saturating conditions (50 µM) led to 
equivalent increases in the froze amide pool when compared with (Mn+2OG)PHD2 
(Table 2.2).  The 50 mM NODD/(Mn+2OG)PHD2 sample exhibited an appreciable 
increase in the frozen amide pool (Afrozen = 70), which is most likely due to solvent 
protection at the binding interface.   A nearly identical increase in the frozen amide pool 
was observed for the 50 mM CODD/(Mn+2OG)PHD2 sample (Afrozen = 73).   The small 
difference in the frozen amide pool between the NODD and CODD samples (DAfrozen = 
3) is within experimental uncertainty, and strongly suggests that both NODD and CODD 
bind to the same surface of PHD2, stabilizing the b2b3 loop to equivalent extents.   
In contrast, the binding of NODD or CODD at low concentrations (20 mM) led to 
different frozen amide pools relative to (Mn+2OG)PHD2 (inset, Figure 2.4).  The large 
difference in frozen amide population for 20 mM NODD binding relative to 20 mM 
CODD binding (DAfrozen = 14) is well outside of experimental uncertainty, and indicates a 
difference in binding equilibrium.  This is most likely due to the stronger binding of 
CODD (KM = 1 mM) relative to NODD (KM = 13 mM), and the position of the ODD + 
PHD2 binding equilibrium.   
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Table 2.2 Global amide HDX kinetics of PHD2.a, b 
 Apo (Mn+2OG) 20 mM 
NODD 
(Mn+2OG)  
20 mM 
CODD 
(Mn+2OG) 
50 mM 
NODD 
(Mn+2OG)  
50 mM 
CODD 
(Mn+2OG)  
Atot 210 ± 1 177 ± 1 171 ± 1 157 ± 1 166 ± 1 163 ± 1 
Afast 160 ± 2 128 ± 2 116 ± 3 85 ± 3 105 ± 3 87 ± 3 
Amed 31 ± 2 31 ± 2 36 ± 3 48 ± 3 42 ± 3 53 ± 3 
Aslow 19 ± 1 18 ± 2 20 ± 2 24 ± 2 18 ± 2 24 ± 2 
Afrozen 26 59 65 79 70 73 
a. Accessible amides: total, Atot; slow, Aslow, (kslow = 0.05 min-1); intermediate, 
Amed (kmed = 1 min-1); fast, Afast (kfast = 20 min-1).   
b. PHD2 (5 µM) in 10 mM NH4OAc pH 7.00, MnSO4 (20 µM) and 2OG (100 
µM); NODD and CODD as indicated.   
 
2.4 Discussion  
The substrate selectivity of PHD2 has been subject to conflicting literature 
reports, which have been clarified with the present work using purified PHD2 and short 
ODD peptides.  Most prior reports indicated that CODD was preferred over NODD, 
however the Michaelis constants (KM) and catalytic efficiency of PHD2 (kcat/KM) have 
been subject to variations of ~ 10-fold.  These variations likely arose from complications 
with the various assays used to measure turnover.  We used kinetic assays that directly 
measure the formation of hydroxylation product (ODDOH) to avoid potential 
complications from uncoupled oxidations or side-reactions that may impede the 2OG 
assay.  Our amide HDX approach directly measured solvent protection upon binding 
NODD or CODD, in order to compare the binding footprints of these two substrates.   
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Our kinetics data indicate that PHD2 prefers the CODD substrate by ~20-fold 
over the NODD substrate (Table 2.1, kcat/KM).  Further, this substrate preference using 
short peptides is sufficient to explain the relative order of hydroxylation observed in 
longer ODD constructs17,18,34, without the need to invoke any sort of sequential cross-
communication between the ODD segments in HIF-1a.  These observations were in good 
agreement with the KM values obtained by the O2-consumption assay22, but differed 
significantly from those obtained by the 2OG assay19,21.  It appears that the 2OG assays 
suffer from non-ideal behavior at low substrate concentrations leading to inflated KM.  
This may be due to uncoupling of oxidative decarboxylation or from non-enzymatic 
decarboxylation, contributing to the observed rates of 2OG turnover.  By measuring 
ODDOH formation directly, the MALDI assay used herein avoided these complications, 
and is recommended for steady-state kinetics assays.   
Direct competitive experiments under varying CODD:NODD ratios (Figure 2.2) 
indicated that PHD2 prefers to hydroxylate CODD, even at low CODD:NODD ratio – 
consequently, CODD should be hydroxylated first under physiological conditions.  This 
is as expected based solely on the catalytic efficiency of PHD2 toward these two 
substrates (Table 2.1).  These results are in accord with a prior competition assay19, 
however our results were obtained at low concentrations of substrate ([NODD] + 
[CODD] = 20 mM), corresponding to conditions appropriate for discussing catalytic 
efficiency.   
The substrate preference of PHD2 is a direct product of the catalytic efficiency  
(kcat/KM) of this enzyme, which is largely a result of differential substrate binding.  A 
minimal kinetic model for catalysis at sub-saturating ODD includes diffusional encounter 
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and release (k1 and k2), a kinetically coupled b2b3 loop closure (k3 and k4), and then 
subsequent steps including the oxidative decarboxylation.  Our results, combined with 
existing structural and protease susceptibility data30,32, indicate that there are two coupled 
steps necessary for substrate binding: diffusional encounter (k1) and b2b3 loop closure 
(k3). 
  
As CODD has 6 negatively charged residues and NODD has only 3 negatively 
charged residues, we thought it likely that electrostatic attraction to PHD2 would be more 
pronounced for CODD than for NODD.  We observed that adding 100 mM NaCl 
decreased the catalytic efficiency of PHD2 toward CODD (kcat/KM) by ~ 3-fold, but had 
no effect on the reaction with NODD (Table 2.1).  This is most likely due to an increase 
in the rate of substrate release (k2) for CODD at elevated [NaCl]; nevertheless, this did 
not equalize the substrate affinity.  We note that CODD remained ~ 7 fold better as a 
substrate than NODD, even at 100 mM NaCl, which requires that a subsequent step 
discriminate these two substrates.  This subsequent step is most likely to be closure of the 
b2b3 loop to adopt a catalytically competent conformation, as seen crystallographically30.  
Notably, PHD2 binding kinetics using substrates very similar to those used herein 
showed that NODD and CODD bound to PHD2 with identical rates, but NODD release 
was ~ 8 times faster than CODD in the presence of elevated [NaCl]19.  This difference in 
binding affinity is in excellent agreement with the difference in catalytic efficiency 
toward the two substrates, which indicates that binding is the principle origin of substrate 
selectivity in PHD2.   
E + ODD ODD/E ODD/E* E + ODDOH
k1
k2
k4
k3
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Previously, protease susceptibility revealed greater protection of the b2b3 loop 
from protease digestion for CODD/PHD2 than for NODD/PHD232, which was 
interpreted to indicate that CODD bound to a larger surface of PHD2 than NODD.  In 
contrast, our global amide HDX data shows that both NODD and CODD protect PHD2 
to identical extents, suggesting that these substrates bind to identical surfaces.  This 
discrepancy arises, in our opinion, from the weaker binding equilibrium for 
NODD/PHD2 than for CODD/PHD2, as shown by the amide protection data shown in 
Figure 2.4.   
The closed conformation of the b2b3 loop in the CODD/PHD2 structure 30 
suggested that loop closure plays a role in catalysis.  We tested the relative ability of 
CODD and NODD to induce the closed conformation of this loop at low and high [ODD] 
concentrations using global amide HDX/MS.  Amide HDX is uniquely capable of testing 
ODD/PHD2 binding, reporting on changes in solvent access upon ODD binding.  NODD 
or CODD led to identical solvent protection when both were present at saturating 
concentrations (50 mM) (Figure 2.4).  The simplest interpretation of this data is that the 
b2b3 loop of PHD2 was stabilized in the closed conformation to the same extent for 
either substrate.   
In contrast, the use of moderate ODD concentrations (20 mM) revealed 
differences in solvent protection (Figure 2.4).  These differences are simply the result of 
the tighter binding of CODD (KM = 1.2 mM), than of NODD (KM = 14 mM); as 
CODD/PHD2 is saturated under this condition, whereas NODD/PHD2 is not saturated – 
CODD/PHD2 is fully protected from solvent whereas NODD/PHD2 is only partially 
protected.  As both NODD and CODD induce identical amide protection when fully 
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saturating, it is very likely that the substrate selectivity of PHD2 does not arise from 
altered ODD/PHD2 contacts, as previously suggested32, but rather from CODD being 
able to push the equilibrium for b2b3 loop closure forward.   
Although the rate-limiting step for PHD2 turnover remains to be identified, this 
step precedes decarboxylation when ODD is saturating, as no oxidized intermediates 
were observed in the pre-steady state35, and a slightly inverse solvent isotope effect on 
kcat was observed23.  The results reported herein suggest that the kinetically coupled 
closing of the b2b3 loop may limit the rate of turnover under conditions of low ODD 
concentration. This has important ramifications for the physiological function of PHD2, 
for two key reasons.  First, it indicates that CODD is hydroxylated before NODD simply 
due to the catalytic efficiency of PHD2 toward these substrates.  Second, it suggests the 
potential to regulate PHD2 function by post-translational modifications that alter the 
charge of either the ODDs or the β2β3 loop of PHD2 (eg: phosphorylation), as this would 
directly impact the ability PHD2 to bind the ODD. 
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CHAPTER III 
THR387 IS THE KEY RESIDUE IN O2 ACTIVATION OF PHD2 
3.1 Introduction 
HIF prolyl-4-hydroxylase 2 (PHD2) is a non heme Fe(II), 2-oxoglutarate (2OG) 
dependent oxygenase that serves as the primary O2 sensor in human cells1,2.  PHD2 
regulates the transcriptional activity of the HIF-1α transcription factor by hydroxylating 
Pro402 and Pro564 within the oxygen dependent degradation domain (ODD) of HIF-1α1,3–5.  
Involvement of HIF-1α in aerobic/anaerobic metabolism, angiogenesis, and 
erythropoiesis makes the PHD2 target for HIF-1α mediated disease6–8.  In order for 
PHD2 function it requires O2, Fe(II), 2OG, and ascorbic acid to keep the Fe(II) in 
reduced state1,9–11.  PHD2 active site is six coordinate, Fe(II) cofactor coordinated with a 
common His2Asp facial triad.  Binding HIF-1α-ODD stimulates hydroxylation by 
PHD212, which is the basis for hypoxia sensing in human cells.  As HIF-1α hydroxylation 
underlies angiogenesis and the balance between aerobic metabolism and fermentation, 
PHD2 is an important therapeutic target for diseases such as ischemia, anemia, and 
cancer6,7.  The mechanical linkage whereby HIF-1α binding stimulates hydroxylation 
chemistry is poorly understood.   
PHD2 is thought to follow the consensus chemical mechanism for 2OG 
oxygenases (Scheme 3.1)12–14.  The (Fe+2OG)PHD2 form of enzyme contains an Fe(II) 
cofactor coordinated by a facial triad, a bidentate 2OG ligand, and an aquo ligand.  When 
substrate ODD binds the enzyme becomes 15-fold more reactive toward O2, which is 
typically attributed to the release of this aquo ligand creating a binding site for O2.  
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Oxidative decarboxylation generates the Fe(IV)-oxo, an intermediate that has been 
observed in other related enzymes12,13,15,16.  This Fe(IV)-oxo hydroxylates the Proline 
residue, regenerating the Fe(II) cofactor (Scheme 3.1).  For those enzymes in which the 
Fe(IV)-oxo intermediate has been observed, product release or decomposition of the 
Fe(IV)-oxo appear to be rate-limiting steps12,13,15,16.  Notably, the HIF hydroxylase 
enzymes appear to be rate-limited by a step associated with O2 binding or activation, as 
the Fe(IV)-oxo intermediate did no accumulate in the pre-steady state for PHD214 and 
both PHD2 and FIH exhibit inverse solvent KIEs17,18. 
The X-ray crystal structure of (Fe+2OG)PHD219 showed that the aquo ligand is 
part of an extended hydrogen bonding network connecting to the second coordination 
sphere.  The network is an extended hydrogen bond extending from the aquo ligand 
through an ordered H2O, which connects the aquo ligand to 2OG and Thr387 (Figure 3.1). 
Thr387 is located on the back beta-sheet at a position that forms a conserved indirect H-
bond to the aquo ligand in many 2OG oxygenases20.  As a step associated with O2 
activation or binding is likely the rate-determining step for PHD2, the disposition of 
Thr387 may be crucial to mechanically link ODD binding to O2 activation and Pro564 
hydroxylation by PHD2.   
Here we tested the role of Thr387 in hydroxylation chemistry by PHD2 through 
point mutagenesis and steady state kinetics.  Both a Thr387 àAla mutation was prepared 
to eliminate H-bonding potential at this site, as well as a conservative Thr387 àAsn 
mutation that would retain the H-bonding potential.  Our steady state kinetic experiments 
indicated that conserving this H-bond led to a mutant enzyme that was very similar to 
WT-PHD2, but that removing this H-bond significantly altered the rate of CODD 
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hydroxylation.  Remarkably, the Thr387àAla mutant hydroxylated CODD 15 times faster 
than WT-PHD2, due to a change in rate-limiting step as shown by an increased SKIE 
(D2Okcat > 1) and an increased kcat/KM(O2) from those observed with WT-PHD2.  This led 
to two important kinetic signatures that we attributed to succinate release becoming the 
rate-limiting step in the Thr387àAla mutant.  First, substrate inhibition of WT-PHD2 was 
not observed, but it became pronounced in the Thr387àAla mutant, which strongly 
implicates succinate release as a slow step in this mutant – a corollary is that other 
substrate inhibition in other 2OG oxygenases likely reflects slow succinate release21.  
Second, the KM(O2) decreased in the Thr387àAla mutant, most likely due to an increased 
rate for O2 activation or decarboxylation.  
 
Scheme 3.1 Consensus chemical mechanism of non heme Fe(II), 2OG dependent 
oxygenases. 
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Figure 3.1 PHD2 active site (PDB ID: 3OUJ). Waters (red sphere), distances (Å). 
3.2 Materials and Methods 
3.2.1 Materials 
All chemicals were purchased from commercial vendors, and used without 
purification.	   	  The sequences of the peptide substrates were derived from the native HIF-
1α556-574 (CODD) sequence.  The sequence of the CODD peptide was 
DLDLEALAP564YIPADDDFQL. The underlined residues were changed from the native 
sequences as follows: CODD (M561A, M568A) to avoid methionine oxidation.  The 
CODD peptide  (99 % purity) was purchased from GL Biochem LTD (Shanghai). 	  
3.2.2 Protein expression and purification 
 Recombinant human PHD2178-426 and its mutants, Thr387àAla and Thr387àAsn 
were expressed as a C-terminal fusion protein from E. coli BL21(DE3) cells using a 
pGEX-4T-1 vector (Stratagene) and purified as previously described18,22.  Briefly, PHD2-
GST was purified using an affinity column (GSTrap, GE Bioscience), then the GST-tag 
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was cleaved with restriction grade thrombin for 16 hours at 4 oC.  The thrombin was 
removed with a Hitrap Benzamidine column (GE Bioscience),  then PHD2 was treated 
with 50 mM EDTA overnight to remove metals. PHD2 was buffer exchanged with 50 
mM HEPES pH 7.50 and stored at -20 oC.  The mass of the WT-PHD2 and the mutants 
were determined by a QStar-XL hybrid quadrupole-TOF mass spectrometer (Applied 
Biosystems).  WT-PHD2 (27786.6 Da calculated, 27784.7 Da observed), Thr387àAla 
(27755.2 Da calculated, 27756.2 Da observed), and Thr387àAsn (27799.6 Da calculated, 
27798.2 Da observed). 
3.2.3 Steady state kinetic assays 
Steady-state kinetic constants were obtained from initial rate measurements using 
MALDI-TOF. 
Initial rates were measured under saturating concentrations of Fe2+ (10 µM) and 
ascorbic acid (1 mM) in 50 mM HEPES buffer pH 7.00 at 37.0 oC.  For assays in which 
[2OG] was varied, the concentration of CODD was fixed at saturating levels for each 
enzyme WT-PHD2 (10 µM), Thr387àAla (10 µM), and Thr387àAsn (10 µM).  Reactions 
were quenched at different time points in saturated 4-α-cyano hydroxycinnamic acid 
dissolved in 75 % acetonitrile and 0.2 % trifluoroacetic acid.  Quenched reactions were 
spotted onto a MALDI target plate and analyzed using a Bruker Daltonics Omniflex 
MALDI-TOF mass spectrometer.  For assays in which the [CODD] varied, the 
concentration of 2OG was fixed at saturating levels for each enzyme WT-PHD2 (100 
µM), Thr387àAla (100 µM), and Thr387àAsn (100 µM).   Observed masses of the 
substrate peptide CODD (M + Na+) 2158 m/z calculated, 2156 m/z observed and 
hydroxylated product CODDOH (MOH + Na+)  2174 m/z calculated, 2172 m/z observed. 
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(Equation 1) 𝜈! =    !!"#  [!]!!![!]  
(Equation 2) 𝜈! =    !!"#!!  !![!]!  [!]!! 
3.2.4 Intrinsic fluorescence quenching 
The dissociation constant (KD) of 2OG was determined by measuring the 
quenching of the intrinsic tryptophan fluorescence of PHD2 upon titrating 2OG using a 
spectrofluorometer (PTI-QM-4 2005SE).  Samples were excited at 295 nm and the 
emission measured at 330 nm.  1 µM PHD2 was titrated with 500 µM 2OG, change in the 
emission intensity at 330 nm upon binding of 2OG was monitored.  KD obtained by 
fitting the data to equation 3. 
Equation 3. !!!!!!!!! = ( ! ! ! !  !!)! ( ! ! ! !!!)!!(! ! ! )![!]  
 
3.2.5 Kinetic solvent isotope effect experiments (KSIE) 
Two different 50 mM HEPES buffers were prepared one with H2O and other with 
D2O mM HEPES buffer prepared using D2O.   Working stock solutions of 2OG, ascorbic 
acid and CODD were prepared in 50 mM HEPES D2O and H2O buffers.  Two different 
set of initial rate measurements performed one with HEPES buffer prepared with H2O 
and the other one with HEPES buffer prepared in D2O, under saturating concentrations of 
Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM) and [CODD] varied from 2 µM to 
10 µM.  KSIE determined as, the ratio of the reaction rate in H2O containing buffer to the 
reaction rate in D2O containing buffer. 
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3.2.6 Determination of KM(O2) 
The initial rate measurements were performed under saturating concentrations of 
Fe2+ (10 µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37 
oC.  The concentration of dissolved O2 was varied by varying the ration of N2 and O2 gas 
flowing through a gas waher in to an Atmosbag (SIGMA), with the dissolved O2 
concentration monitored by a YSI model 5300 biological oxygen monitor.  Reactions 
were quenched and analyzed as for other steady state reactions.  
3.3 Results 
3.3.1 Steady state kinetics with varied [2OG] 
The initial rate data for WT-PHD2 and the Thr387àAla/Asn were measured as a 
function of varied [2OG] using saturating concentrations of Fe2+ (10 µM), CODD (10 
µM), and ascorbate (1 mM); [O2] was fixed at ambient levels (217 uM).  WT-PHD2 
exhibited simple saturation kinetics over the range of 1 –200 µM 2OG, with fitted values 
of kcat  (2.4 min-1) and kcat/KM(2OG) (2.03 µM-1min-1) similar to those previously 
reported18,22–25.  Similarly, the Thr387àAsn mutant exhibited saturation kinetics over the 
tested concentration range, with modestly decreased rate constants (kcat = 1 min-1, 
kcat/KM(2OG) = 1.5 µM-1min-1) (Table 3.1). 
The initial rate data for Thr387àAla was a significant contrast to that of WT-
PHD2.  The initial rate for product formation was measured at varied [2OG], with the 
concentration of all other reagents fixed as above with the exception of CODD (10 µM). 
Thr387àAla exhibited simple saturation kinetics for [2OG]<500 µM, however the kinetic 
data for this mutant suggested the potential for substrate inhibition.  Initial rate data over 
a wider concentration range showed ~50% inhibition at 3000 µM 2OG (Figure 3.2).  
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Fitting the initial rate data to the inhibition model led to fitted parameters of kcat (32.92 
min-1), kcat/KM(2OG) (2.7 µM-1min-1), and KI(2OG) (2200 µM) indicative of substrate 
inhibition.  The high value for kcat indicated that Thr387àAla could perform chemistry 
more rapidly than WT-PHD2, but the observed substrate inhibition suggested that slow 
product release could limit turnover.  
The substrate inhibition observed for Thr387àAla prompted us to test the other 
variants for this effect.  WT-PHD2 exhibited 5% inhibition at extremely high levels of 
2OG; and fitting this data to the model substrate inhibition model did notsignificantly 
change the steady state rate constants, kcat (2.3 µM), kcat/KM(2OG) (2.7 µM-1min-1), and 
KI(2OG) (>25 mM) suggested that substrate inhibition was not pronounced for WT-PHD2. 
Thr387àAsn similarly showed minimal inhibition at extremely high 2OG concentration, 
with steady state rate constants virtually unchanged, kcat (1.0 min-1), kcat/KM(2OG) (1.5 µM-
1min-1), and a very large estimate for KI(2OG) (>50000 µM) (Figure 3.3).  The absence of 
significant substrate inhibition observed for WT-PHD2 and for Thr387àAsn mutant was 
consistent with product release being rapid in these enzymes, consistent with the prior 
reports that implicated a step early in catalysis as being rate-limiting for WT-PHD2. 
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Figure 3.2 Thr387àAla shows inhibition at high 2OG concentration.  Reaction mixture 
includes, Thr387àAla, (0.3 μM), (NH4)2Fe(SO4)2 (10 μM), ascorbic acid (1 mM), 2OG 
(1-1000 µM), and CODD (10 μM) in 50 mM HEPES pH 7.00, 37°C, ambient [O2](217 
μM). 
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Figure 3.3 Determination of steady state kinetic constants kcat /KM(2OG) for WT-PHD2 
and Thr387àAsn.  Graph A is WT-PHD2 and graph B is Thr387àAsn.  Reaction mixture 
includes, WT-PHD2 or Thr387àAsn, (1 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 
mM), 2OG (1-3000 µM), and CODD (10 µM) in 50 mM HEPES pH 7.00, 37°C, ambient 
[O2](217 µM). 
 
Table 3.1 Steady state kinetics of WT-PHD2 and mutants with varied [2OG]. 
Enzyme kcat  
min-1 
kcat/KM  
µM-1min-1 
KI(2OG)  
µM 
KM(2OG), 
µM 
KD(2OG) 
µM 
WT-PHD2 2.3 ± 0.1 2.7 ± 0.4 >2.6x104 0.9 ± 0.2 0.7 ± 0.2 
Thr387àAla 32.9 ± 1.4 2.7 ± 0.3 2150 ± 338 12.0 ± 1.6 1.2 ± 0.2 
Thr387àAsn 1.0 ± 0.1 1.5 ± 0.2 >5x104 0.7 ± 0.1 0.6 ± 0.2 
 
3.3.2 Binding constants for 2OG 
Intrinsic tryptophan fluorescence was monitored upon binding 2OG to determine 
the binding constant for the PHD2 + 2OG ⇔ PHD2/2OG equilibrium.  WT-PHD2 and 
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Thr387àAla were excited at 295 nm and the emission was monitored at 330 m upon 
titration with 2OG then the data were fitted to the equation 3 (Figure S1).  Each enzyme 
bound 2OG with similar affinity, as shown by the KD for WT-PHD2 (0.8 µM), 
Thr387àAla (1,2 µM) and Thr387àAsn (0.6 µM) had a (Table 3.1), indicating that 
mutation of Thr387 did not significantly alter the binding of 2OG.   
 
 
Figure 3.4 Determination of KD(2OG) for WT-PHD2, Thr387àAla and Thr387àAsn 
upon intrinsic fluorescence quenching of tryptophan upon binding of 2OG to the enzyme 
active site.  Closed circles WT-PHD2 (1.1 µM), open circles Thr387àAla (1 µM ), 
triangles Thr387àAsn (1.1 µM), each with MnSO4 (20 µM) in 50 mM HEPES pH 7.00 
titrated with 2OG (500 µM). 	  
3.3.3 Steady state kinetics with varied [CODD] 
The initial rates of CODD hydroxylation were measured as a function of varied 
CODD concentration for WT-PHD2 and the point mutants ain 50 mM HEPES (pH 7.00, 
37°C), with saturating concentrations of Fe2+ (1 µM), 2OG (100 µM), and ascorbate (1 
mM); the [O2] was fixed at ambient conditions (217 mM nominally).  Steady state 
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constants, kcat, and kcat/KM(CODD), were determined by fitting the data to the Michaelis-
Menten equation.  The rate constants for WT-PHD2 at saturating [CODD] was kcat = 1.9 
min-1, and kcat/KM(CODD) = 2.4 µM-1min-1), were in good agreement with prior 
reports18,23,26.  The conservative Thr387àAsn mutant exhibited rate constants (kcat 0.9 
min-1, kcat/KM= 0.7 µM-1min-1) that were modestly decreased from those of WT-PHD2, 
suggesting that Thr387àAsn mutation did not alter hydrogen bonding within the active 
site (Figure 3.5).  In contrast, the Thr387àAla mutant exhibited initial rates that were 
much faster than those of WT-PHD2, as well as pronounced inhibition at elevated CODD 
concentrations (Figure 3.6).   
The initial rate data for Thr387àAla was fitted in two ways in order to adequately 
treat the inhibition.  The first fitting attempted used the Michaelis-Menten equation to fit 
the initial rate data from 0 – 10 µM, leading to fitted parameters of kcat = 32.5 min-1 and 
kcat/KM = 13 µM-1min-1.  These kinetic constants were remarkable because they indicated 
that removing the hydrogen bonding group from position 387 led to an enzyme that was 
15 times more reactive than WT-PHD2, suggesting that WT-PHD2 was not fully 
optimized for maximal turnover frequency.  The very high kcat value for this mutant 
indicated that the rate-limiting step became faster as compared to WT-PHD2 – this step is 
likely decarboxylation of 2OG for WT-PHD2.  However, this fit was not good, as 
indicated by the systematic derivation between the fitted curve and the data. and 
succinate release for Thr387àAla (see discussion).  The second fitting attempted used the 
substrate inhibition model and resulted in kcat = 44 min-1, kcat/KM = 11 µM-1min-1, and KI 
= 39 µM (Table 3.2).  This second fit reproduced the data well, revealing that the peptide 
substrate (CODD) inhibited Thr387àAla rather strongly. 
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Figure 3.5 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2 and 
Thr387àAsn.  Triangles WT-PHD2 and circles are Thr87àAsn.  Reactions include, WT-
PHD2 (1 µM) or Thr387àAsn (2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 
2OG (100 µM), and CODD (2-40 µM) in 50 mM HEPES pH 7.00, 37°C, ambient 
[O2](217 µM). 
 
Figure 3.6 Substrate inhibition for Thr387àAla at high CODD concentration. Reaction 
mixture included Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 
2OG (100 µM), and CODD (2-50 µM) in 50 mM HEPES pH 7.00, 37°C, ambient 
[O2](217 µM).  Insert is the steady state kinetics between 2 µM to 50 µM CODD. 
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Table 3.2 Steady state kinetic constants, kcat and kcat/KM of WT-PHD2, Thr387→Ala and 
Thr387→Asn for CODD substrate peptide.	  	  
Enzyme kcat ,min-1 kcat/KM(CODD), µM-1min-1 KI, µM KM, µM 
WT-PHD2 1.9 ± 0.1 2.4 ± 0.2 - 0.8 ± 0.1 
Thr387→Ala 44.4 ± 3.3 10.8 ± 1 38.4 ± 6.4 4.1 ± 0.7 
Thr387→Asn 0.9 ± 0.1 0.7 ± 0.1 - 1.4 ± 0.2 
 
3.3.4 Kinetic SIE on kcat 
Solvent isotope effects (SIEs) are unique measurements that reveal the rate-
limitation of steps associated with proton motion or with the release of aquo ligands from 
metal ions35.  As aquo release is a curicial step preceding O2 activation in the 2OG 
oxygenases KSIEs can reveal whether an early step or a late step is rate limiting on kcat.  
In the case of WT-PHD2, an inverse kinetic SIE was observed on kcat ((SIE)kcat = 0.75), 
indicating that an irreversible step after aquo release was partially rate-limiting on kcat18.   
The kinetic SIE was measured in 50 mM HEPES buffer pH/pD = 7.00 for WT-
PHD2 and the point mutants.  (SIE)kcat was inverse for both WT-PHD2 (0.75) and for 
Thr387àAsn (0.81), which indicated a pre-equilibrium aquo release immediately 
preceded the rate-limiting step (Figure 3.7 panel A)35. In contrast, the kinetic SIE for 
Thr387àAla was normal ((SIE)kcat = 2.92), which indicated that proton transfer was rate-
limiting on kcat for this mutant (Figure 3.7 panel B)35. 
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Figure 3.7 Solvent isotope effect on WT-PHD2, Thr387àAla, and Thr387àAsn.  WT-
PHD2 in D2O buffer (▲), WT-PHD2 in H2O buffer (Δ); Thr387àAsn in D2O buffer (■), 
Thr387àAsn in H2O (☐).  Thr387àAla in D2O buffer (●); H2O buffer (○). Reactions 
include, WT-PHD2 (1 µM), Thr387àAla (1 µM), or Thr387àAsn (0.3 µM), 
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (10 µM) in 
50 mM HEPES pH 7.00 or pD 7.00, 37°C, ambient [O2](217 µM). 	  
Table 3.3 SIE kinetic parameters for PHD2 and its variants. 
Enzyme Hkcat ,min-1 Dkcat, min-1 SIE(kcat) 
WT-PHD2 1.9 ± 0.1 2.6 ± 0.2 0.8 
Thr387àAla 32.5 ± 2.5 11.1 ± 0.2 2.9 
Thr387àAsn 0.9 ± 0.1 1.1 ± 0.1 0.8 
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3.3.5 Steady state kinetics with varied [O2] 
The initial rates were measured as a function of varied O2 concentration using 
saturating concentration of Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM), and 
CODD (10 µM).  The initial rate data for WT-PHD2 and Thr387àAsn showed simple 
saturation kinetics over the range of 6 µM to 1 mM O2 concentration and was fitted to the 
michealis-menten equation, KM(O2) (527.33 µM, 757.01 µM) and kcat/KM(O2) (0.015 µM-
1min-1, 0.05 µM-1min-1) (Figure 3.8).  Thr387àAla mutant exhibited normal saturation 
kinetics between 6 µM to 217 µM O2 range, with the kinetic parameters of KM(O2) (102 
µM) and kcat/KM(O2) (0.3 µM-1min-1) (Figure 3.9).  But interestingly Thr387àAla inhibited 
at higher than 217 µM O2 concentration.  Fitting the initial rate data to an inhibition 
model led to kinetic parameters of kcat (401 min-1), kcat/KM(0.35 µM-1min-1) and KI(11 
µM) (Table 3.4). 
 
Figure 3.8 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2 and 
Thr387àAsn.  Reaction mixture includes, WT-PHD2 (1 µM) or Thr387àAsn (2 µM), 
(NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), CODD (10 µM), and ascorbic acid (1 mM) in 
50 mM HEPES pH 7.00.  Open circles are WT-PHD2 and the closed circles are 
Thr387àAsn. 
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Figure 3.9 Steady state kinetics constants kcat (O2) and kcat/KM (O2) for Thr387àAla.  
Reaction mixture includes, Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), 2OG (100 
µM), CODD (10 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00.  Insert, 
steady state kinetics of Thr387àAla between 6 µM to 760 µM O2. 	  	  
Table 3.4 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2, 
Thr387àAla, and Thr387àAsn. 
 
Enzyme kcat ,min-1 kcat/KM, µM-1min-1 KM, µM KI, µM 
WT-PHD2 (1) 8 ± 0.7 0.015 ± 0.001 530 ± 90 - 
Thr387→Ala (1) 28.3 ± 2.6 0.3 ± 0.1 102 ± 22 - 
Thr387→Ala (2) 401 ± 14 0.4 ± 0.1 1136.9 ± 158 11 ± 00 
Thr387→Asn (1) 3.8 ± 0.5 0.005 ± 0.001 757.03 ± 168 - 
(1) is fit equation 1 and  (2) is fit for equation 2. 
[Fe2+] = 10 µM, [2OG] = 100 µM, [CODD] = 10 µM, 37 oC, pH 7.00. 
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3.3.6 Inhibition by added succinate 	   Effects of succinate on WT-PHD2 and Thr387àAla activity tested at varied [2OG].  
Activity assays performed with ascorbic acid (1 mM), (NH4)2Fe(SO4)2 (10 µM), 2OG (2-
100 µM), and succinate (0 – 1 mM) in an air saturated 50 mM HEPES pH 7.00 at 37 OC.  
Initial rates were obtained as described earlier and KI(Succinate) obtained by plotting the 
initial rate vs [2OG] for each [Succinate] and data fitted to competitive inhibition 
equation (equation 3) using global fitting setting in Origin. WT-PHD2 and Thr387àAla 
had different KI(Succinate), 490 µM and 260 µM, respectively.   
 
 
Figure 3.10 Inhibition of WT-PHD2 and Thr387àAla.  Upper panel is WT-PHD2 and the 
lower panel is Thr387àAla.  Reaction includes, ascorbic acid (1 mM), (NH4)2Fe(SO4)2 
(10 µM), PHD2 (0.15-1 µM), 2OG (2-100 µM) and succinic acid (0-1 mM) in an air 
saturated 50 mM HEPES pH 7.00 at 37 oC. 	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Table 3.5 WT-PHD2 and Thr387àAla KI(Succinate). 
Enzyme kcat, min-1 KI(Succinate), µM 
WT-PHD2 2.7 ± 0.3 491 ± 74 
Thr387àAla 33.2 ± 0.5 261 ± 50 
 
3.4 Discussion 
Mutation of Thr387 to remove the second-sphere hydrogen bond to the coordinated 
aquo ligand led to significant changes in the kinetic constants and inhibition patterns of 
PHD2.  These changes in observed parameters arise due to a change in rate-limiting step 
for the Thr387àAla mutation, which unmasks product release in this mutant.  This 
implicates the hydrogen bond from Thr387 in impeding the ability of O2 to react at the 
Fe(II) center, and points to this residue as being a key component in the mechanical 
linkage that stimulates hydroxylation in PHD2 once HIF-1α-ODD binds.   
Thr387àAla alters the rate-limiting step(s). 
The Thr387àAla mutation changes the rate-limiting step on kcat for PHD2, from a 
step involved with O2 binding/activation in WT-PHD2 to product release step.  The 
observation of increased kcat for Thr387àAla is unusual, as point mutations typically 
attenuate catalytic power in enzymes.  That this mutation leads to an increased kcat 
indicates that one or more microscopic steps have increased in rate.  The simplest way to 
increase kcat for this mutant would be to increase the rate of the rate-limiting step for WT-
PHD2, which is most likely a step associated with O2 binding/activation.  That O2 
binding/activation is rate-limiting for WT-PHD2 relies on the observation of an inverse 
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SKIE on kcat (Dkcat = 0.8)18, indicating that the rate-limiting step is an irreversible step 
after aquo release, and the absence of any oxidized intermediate in the pre-steady state, 
Bollinger  which indicates that HAT/rebound are fast.  The observation of a large, normal 
SKIE for Thr387àAla (D2Okcat = 2.9) excludes this possibility for the mutant, and is most 
consistent with a product release step as rate-limiting on kcat. 
A simple model that accounts for the normal SKIE and the substrate inhibition 
found for Thr387àAla is one in which either succinate release becomes slow in this point 
mutant, such that the (Fe+succ)PHD2 form of enzyme would accumulate in the steady 
state.  Inhibition by 2OG or by CODD would arise from these substrates binding to the 
enzyme, thereby preventing the enzyme from adopting the proper cofactor orientation to 
enter into catalysis.  This is in contrast to WT-PHD2, for which a step prior to HAT is 
likely rate-limiting meaning that the accumulating enzyme form is 
(Fe+2OG+CODD)PHD2 – WT-PHD2 does not experience substrate inhibition because a 
second molecule of 2OG or CODD cannot bind to this enzyme form.   
Binding of CODD peptide to (Fe+succ)PHD2 simply requires that the enzyme 
can adopt a closed conformation22,27,28, but binding of 2OG to this form of enzyme would 
require that both succinate and 2OG simultaneously bind to the cofactor.  Precedent for 
the Fe(II) cofactor binding two carboxylic acids comes from the 2OG-substrate inhibition 
observed from histone demethylases21.  We note that an alternate possibility is that CO2 
release is the slow step for Thr387àAla.  Although CO2 release is typically indicated as 
preceding hydroxylation in the consensus mechanism, an intriguing possibility is that 
CO2 release from Fe occurs through hydrolysis, to form carbonic acid directly – but this 
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is simple speculation.  In either case, the binding of 2OG or CODD to an enzyme/product 
form would impede turnover in Thr387àAla.   
Thr387àAla increases O2 reactivity  
Comparison of the steady-state rate constants reveals that removing the hydrogen 
bond from Thr387 specifically increases the rate of step(s) associated with O2 activation.  
As understanding how substrate binding stimulates O2 activation is crucial to figuring out 
how the HIF hydroxylases respond to changes in pO2, we focused our attention on kinetic 
constants reporting on O2 activation.  Only those kinetic constants reporting on O2 
activation increased in magnitude for the Thr387àAla mutant relative to WT-PHD2, 
indicating that removal of this hydrogen bond accelerated O2 activation.  This in turn 
suggests that the indirect hydrogen bond from Thr387 is a central piece of the mechanical 
linkage that stimulates O2 activation only after CODD binds.   
As the second-order rate constant (kcat/KM(O2)) report on steps between binding of 
O2 and the subsequent irreversible step, inspection of a kinetic mechanism for PHD2 
shows that that these steps consist of reversible O2 binding (k5, k6) and oxidative 
decarboxylation (k7).  Our experimental conditions used saturating levels of 2OG and 
CODD, such that our reported values for kcat/KM(O2) are isolated on these steps.  Both 
WT-PHD2 and the conservative Thr387àAsn mutant exhibit rather sluggish reactivity 
toward O2, with kcat/KM(O2) = 0.015 µM-1min-1 (~ 0.25 x 10-9 M-1 sec-1), consistent with 
prior reports29,30  The Thr387àAla mutant is a contrast to this, as kcat/KM(O2) = 0.3 µM-1 
min-1, a 20-fold increase in reaction rate which indicates that step(s) involving O2 
activation have markedly increased in rate for this point mutant.  The increased kcat and 
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kcat/KM(CTAD) observed for Thr387àAla further point to acceleration of oxidative 
decarboxylation in this mutant over that observed for WT-PHD2.  
The inactivation of Thr387àAla at elevated [O2] further suggests that oxidative 
decarboxylation is much faster in this mutant than in WT-PHD2 (Figure 3.9). We 
attempted to fit this inactivation profile to a model in which O2 acted as an inhibitor, but 
could not obtain a satisfactory fit to the model.  A second possibility, that of succinate 
inhibition, was tested (Figure 3.10) but similar inhibition constants were observed for 
both WT-PHD2 (KI(Succinate) = 491 µM) and Thr387àAla (261 µM).  We propose that 
this inactivation arises from auto-oxidation or an internal auto-hydroxylation of a PHD2 
residue, as is seen for several other 2OG oxygenases31–34. 
Implications for substrate-stimulating hydroxylation  
The acceleration in the O2-activation rate for Thr387àAla suggest that this mutant 
has perturbed the chemical mechanism of PHD2 in such a way that O2-activation is 
accelerate the Thr387àAla mutant implies that this hydrogen bond is a key component of 
the mechanical linkage leading to hydroxylation chemistry.   
 
 
 
Scheme 3.2 Steps in the chemical mechanism of Thr387àAla showing the 
inhibition mechanism by 2OG. 
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Scheme 3.3 Steps in the chemical mechanism of Thr387àAla showing the 
inhibition mechanism by CODD. 
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CHAPTER IV 
PHD2 HAS A Zn(II) BINDING ALLOSTERIC SITE 
4.1 Introduction 
The cellular response to the challenge of low pO2 (hypoxia) is curial to tissue 
development, with the transcriptional level of hundreds of genes controlled by HIF-1α 
controlled genes include those associated with balancing aerobic an anaerobic 
metabolism, as well as angiogenesis and erythropoiesis1–3.  A small group of four 
oxygenase enzymes regulate the activity of HIF-1α, with the HIF-prolyl hydroxylase 2 
(PHD2) viewed as the primary cellular oxygen sensor in humans4–6.  PHD2 hdroxylates 
Pro402 and Pro564 within the N- and C- terminal oxygen degradation domain of HIF-1α, 
leading to the proteasomal degradation of HIF-1α7–9.  Consequently, PHD2 and the other 
HIF hydroxylases are therapeutic targets for diseases such as cancer and ischemia10,11. 
 
PHD2 is a member of a superfamily of 2OG dependent non heme Fe(II) 
dioxygenase (2OG oxygenases) that hydroxylates carbon rich substrates via oxidative 
decarboxylation of 2OG1,5,12,13.  The balanced reaction for PHD2 is: O2 + 2OG + Pro 
→ CO2 + succinate + Pro-OH in which Pro = Pro402 and Pro564.  As for other members 
of this superfamily, the Fe(II) cofactor in resting enzyme in bound by a 2HisAsp facial 
triad (His313, His374, and Asp315), a bidentate 2OG, and a labile ligand that s typically 
H2O.  PHD2 is unusual as it binds Fe(II) tightly (KM ~ 0.03 µM)14, in constant to other 
members of this superfamily (KD ~ 1-10 µM)15,16. 
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 A number of metals and 2OG-mimics are known to inhibit the 2OG oxygenases, 
including PHD217,18,19–21.  The active site of 2OG oxyganses tolerate the later transition 
metals as evidenced by in vitro and in vivo experiments18,22.  X-ray crystal structures 
containing Mn2+, Zn2+, Co2+, as well as the other spectroscopic studies of 2OG oxyganses 
constituted with Cu2+ and Co2+, demonstrate that the active site of 2OG oxyganeses can 
be constituted with numerous metals.  PHD2 is no exception, with structures containing 
Mn2+ and Zn2+ has been crystalized23–25.  Similarly, a wide variety of chelates displace 
2OG in vitro, as shown by enzyme inhibitor screens.  Furthermore elevated levels of 
metabolic intermediates, such as succinate and alpha-hydroxyglutarate, can displace 2OG 
under conditions of over abundance and impact the activity of 2OG oxygenases, 
including PHD2. 
 
 The literature contains conflicting data regarding the in vivo and in vitro inhibition of 
2OG oxygenase by metal ions.  In vitro assays generally show that d-block metals bind to 
the active site of 2OG oxygenases with KD ~10 µM, however PHD2 is a notable 
exception14,15.  In vivo metal displacement at histone and nucleotide demethylases has 
been proposed o lead to a number of epigenetic changes, with active site binding metals 
shown in vitro 18.  Although Co2+, metal chelators, and DMOG are commonly used to 
induce hypoxia sensitive gene expression within cell culture, recent reports suggest that 
various HIF hydroxylases are differentially inhibited by these agents in the cells14.  The 
mechanism of enzyme inhibition has ben attributed to competition with Fe2+ for the 
active site, ascorbic acid depletion, or effects remote from the active site. 
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PHD2 is particularly confounding, as the apparent inhibitory effects of different 
metal ions depend greatly on sample history, and the presence of a second site for metal 
binding.  Purified PHD2 retains significant activity and Fe2+ content due to the tight 
binding of Fe2+, which leads samples of PHD2 to contain variable metal unless the metal 
is specifically removed by extended treatment with EDTA.  The IC50 for d-block metals 
toward purified PHD218,22 was significantly lower than toward crude PHD2 suggesting 
that leaching of Fe2+ from the active site during purification made PHD2 more 
susceptible to exogenous metals.  Similarly, PHD2 exhibits only partial inhibition with 
certain metals, and purified PHD2 was shown to bind two metal ions under certain 
conditions; one at the active site and the other at a surface site requiring Cys201 26.  
Consequently, the inhibition noted for PHD2 may simply depend on whether the species 
present at the time of metal competition is (Fe)PHD2, (Fe + 2OG)PHD2, or apo PHD2, 
as well as whether or not the surface site can be accessed. 
Regulating enzyme activity through allosteric binding site is a strategy used for 
many important cellular processes, particularly those necessary for adopting to alter 
growth conditions.  Hypoxia is an existential challenge for higher organisms, as complex 
tissues experience varied levels of pO2 under normal conditions, with even more complex 
gradients of pO2 under the challenge of disease or toxicity.  The centrality of hypoxia 
sensing to development responses makes understanding those factors impacting hypoxia 
sensitive gene expression crucial for health and disease. 
The surface metal binding site is intriguing, due to the MYND in full length 
PHD2.  In this work coordination of the surface site have been identified as Cys201, 
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Cys208, Tyr197, His205, and two water ligands.  Metal inhibition assays suggest that this 
this site can possibly be targeted for control the enzyme activity. 
 
Figure 4.1 A) Allosteric site showing the Zn2+ binding residues, H2O (red sphere) PDB 
ID: 2G19.  B) PHD2 active site showing the Fe2+ and coordinating residues, H2O (red 
sphere) PDB ID: 3OUJ. 	  
4.2 Experimental procedures 
4.2.1 Materials 
All the chemicals were purchased from chemical vendors, and used without 
further purification.  The ODD peptide was DLDLEALAP564YIPADDDFQL. The 
underlined residues were changed from the native sequences as follows: M561A, M568A 
to avoid methionine oxidation and was purchased from GL Biochem LTD (Shanghai) (99 
% purity).  For Cys201àAla mutation primers, 5`-
GTGCTTGTTCATGGCCGGCACGATGTACTCGAGC-3` and 5`-
GCTCGAGTACATCGTGCCGGCCATGAAGCAC-3` has been used (IDT). 
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4.2.2 Protein expression and purification  
The recombinant WT-PHD2 and Cys201àAla mutant were expressed in E. coli 
BL21(DE3) cells using a pGEX-4T-1 vector (Stratagene) with an N-terminal GST tag.  
The GST-PHD2 fusion protein was purified using an affinity column (GSTrap, GE 
Bioscience), then the GST tag was removed by incubating in restriction grade thrombin 
(1 unit thrombin/ mg PHD2) for 16 hours at 4 oC.  Following thrombin removal using a 
Hitrap Benzamidine column (GE Bioscience), GST-tag was removed by GSTrap column.  
Purified PHD2 was incubated with 50 mM EDTA overnight at 4 oC, then buffer 
exchanged with 50 mM HEPES 150 mM NaCl pH 7.50 for storage at -20 oC.  
4.2.3 Initial rate measurements 
PHD2 and Cys201àAla activities were determined by direct measurement of the 
hydroxylation of Pro564 residue in 19 residue fragment of ODD domain using Bruker 
Daltinics Omniflex MALDI-TOF mass spectrometer.  Initial rates (ν0) were obtained 
from change in mol fraction of hydroxylated ODDOH (χODDOH) equation 4.1 
Equation 4.1 𝜐!   = [𝑂𝐷𝐷]!𝜒!""!#/𝑡 
For steady state kinetic assays, all the saturating concentrations of reagents were 
used. Reaction mixture includes, PHD2 (1 µM), 2OG (100 µM), (NH4)2Fe(SO4)2 (10 
µM), M(SO4) (50 µM), ascorbic acid (1 mM) and ODD (20 µM).   
4.2.4 Metal inhibition assays 
All the activity assays were performed with PHD2 (1 µM) and saturating 
concentrations of ascorbic acid (1 mM), 2OG (100 µM), and (NH4)2Fe(SO4)2 (10 µM) in 
50 mM HEPES pH 7.00 at 37 oC. In metal competition assays 10 µM (NH4)2Fe(SO4)2 
and varying concentrations of M(SO4) (M, Zn, Co, Mn, Ni, Cu) from 5 µM to 200 µM 
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were used.  In one set of experiments (NH4)2Fe(SO4)2 and M(SO4) were added to PHD2 
at the same time and incubated with the enzyme for 3 minutes.  After 3 minutes 
incubation of PHD2 with the two metals, the reaction was initiated by addition of 20 µM 
ODD.  Aliquots were quenched with 2:1 ratio of acetonitrile and 0.2 % trifluoroacetic 
acid saturated with 4-α-cyanohydroxycinnamic acid at different time points (20 second to 
3 minutes).  In a second set of experiment the enzyme pre-incubated with 10 µM 
(NH4)2Fe(SO4)2  100 µM 2OG, and 1 mM ascorbic acid for 3 minutes. After 3 minutes 
incubation reaction second metal (MSO4) was added and the reaction mixture incubated 
additional 3 more minutes then the reaction was initiated by adding 20 µM ODD. 
4.2.5 X-ray Absorption Spectroscopy Sample Preparation 
XAS samples were prepared by mixing PHD2 (1 mM) with 1 mM 
(NH4)2Fe(SO4)2 and 1mM 2OG in an air saturate buffer (50 mM HEPES 150 mM NaCl 
pH 7.50) for 15 minutes on ice.  Samples were then treated with chelex for 30 minutes to 
remove unbound Fe2+ from samples. After treatment removal with chelex, chelex 
removed by centrifuging the samples and removing the sample with a pipette.  Then 0.9 
mM of ZnSO4 or NiSO4 was added to the PHD2 samples, which were incubated on ice 
10 more minutes.  Each sample was loaded to XAS sample holder and immediately 
frozen in liquid N2.  
4.3 Results 
4.3.1 PHD2/Cys201àAla has different inhibition profile with different addition 
order of metals 
When WT-PHD2 was incubated with Fe2+ and divalent transition metals, Zn2+, Mn2+, 
Co2+, Cu2+, or Ni2+, each lead to a strong inhibition of WT-PHD2 except NiSO4, which 
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partially inhibited the enzyme by only 20 % (Figure 4.1 panel A).  The inhibitory effects 
of 10 µM metal followed the trend Cu>Zn>Co,Mn>>Ni, which is consistent with the 
Irving William series with the exception of Ni.  Pre incubation of WT-PHD2 with Fe2+ 
mostly prevented the inhibition of enzyme by retaining the activity of WT-PHD2 up to 
65-80 % at 200 µM metal concentration, except for Cu2+, which lead to a strong 
inhibition (Figure 4.1 panel B).   
 
The inhibition profile in Figure 4.2 suggested that inhibition was allosteric.  Since 
a previous study showed that two metal ions can be bind to PHD2 and that mutation of 
Cys201 to Ala prevented the binding of two transition metals26, we purified the 
Cys201àAla mutant and tested it for metal inhibition. Under competitive assay 
conditions, each of the late 3d metals inhibited the Cys201àAla mutant similarly to WT-
PHD2.  When Cys201àAla was pre incubated with Fe2+ then tested with metals, overall 
inhibition trend was very similar to that observed for WT-PHD2, with only Cu2+ 
inhibiting the enzyme by more than 50 %  (Figure 4.2 panel B). 
 
Inhibition profile where the WT-PHD2 pre incubated with Zn2+, Co2+, Mn2+, and 
Ni2+ and increasing concentration of Fe2+ (from 10 µM to 200 µM) added, shows that 
Fe2+ can not displace these metal from active site except for the Ni2+.  Increasing [Fe2+] 
up to 200 µM  enzyme gained its activity by 30 % (Figure 4.3). 
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Figure 4.2 Inhibition of WT-PHD2 from concentration of 10-200 µM M2+ (M2+ =  Mn2+, 
Co2+, Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with cofactor 
Fe2+ and co-substrate 2OG.  Panel B, second metal MSO4 added after pre incubated WT-
PHD2 with Fe2+.  Reactions performed with WT-PHD2 (1 µM), 2OG (100 µM), 
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and ODD (20 µM) 
in 50 mM HEPES pH 7.00 at 37 oC. 
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Figure 4.3 Inhibition of Cys201àAla from concentration of 10-200 µM M2+ (M2+ = 
Mn2+, Co2+, Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with 
cofactor Fe2+ and co-substrate 2OG.  Panel B, second metal MSO4 added after pre 
incubated the Cys201àAla with Fe2+.  Reactions performed with WT-PHD2 (1 µM), 2OG 
(100 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and 
CODD (10 µM) in 50 mM HEPES pH 7.00 at 37 oC. 	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Figure 4.4 Inhibition of WT-PHD2 by Mn2+, Co2+, Ni2+, and Zn2+ when PHD2 pre 
incubated with one of these metals then increasing [Fe2+] from 10 µM to 200 µM.  
Reactions performed with WT-PHD2 (1 µM), 2OG (100 µM), MSO4 (10 µM), ascorbic 
acid (1mM), (NH4)2Fe(SO4)2 (0-200 µM) and CODD (20 µM) in 50 mM HEPES pH 7.00 
at 37 oC. 	  
	  
Figure 4.5 inhibition of WT-PHD2 by Mn2+, Co2+, Ni2+, and Zn2+ when (Fe2+)PHD2 
incubated with one of these metals for three hours.  Reactions performed with WT-PHD2 
(1 µM), 2OG (100 µM), MSO4 (50 µM), ascorbic acid (1mM), (NH4)2Fe(SO4)2 (10 µM) 
and CODD (20 µM) in 50 mM HEPES pH 7.00 at 37 oC. 
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4.3.2 Addition of second metal does not change KM(CODD) except for the Co2+, and 
Zn2+. 
Saturating concentrations of Fe2+(10 µM), 2OG (100 µM), ascorbic acid (1 mM) 
and 50 µM test metal used as this was saturated for the inhibition curves and ODD varied 
to test for inhibition of E and ES form of the enzyme.  Steady state kinetic measurements 
indicate that addition of test metal to PHD2 led to modest inhibition of kcat but more 
pronounced effect on kcat/KM(CODD) (Table 4.1).  To the predominant enzyme form under 
conditions of saturating [ODD] is the ES form, this is indicates that the added metals 
modestly slowed the ES →→ E + P conversion.  In contract free E dominates under 
saturating [ODD], and kcat/KM(CODD) effects on the E + S ⇔ ES  → EP steps.  As these 
steps were slowed markedly  (M = Zn2+ and Co2+) its is likely that Co2+ and Zn2+ altered 
PHD2’s affinity to substrate ODD by 2 to 3 fold, possibly due to a conformational 
change. 
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Figure 4.6 Steady state kinetics for WT-PHD2 pre incubation with Fe2+ (10 µM), 2OG 
(100 µM) and 50 µM M2+ (Mn2+, Co2+, Ni2+, or Zn2+). Reactions were performed, 1 µM 
WT-PHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM), M2+ 
(50 µM) and ODD (2-20 µM) in 50 mM HEPES pH 7.00 at 37 oC. 
 
Table 4.1 Steady state kinetic constants in the presence of 50 µM Mn2+, Co2+, Ni2+, or 
Zn2+ for WT-PHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 
mM). 
 
Enzyme    kcat (min-1)       kcat/KM (µM-1min-1)    KM (µM) 
(10Fe)PHD2   1.9 ± 0.1         2.5 ± 0.2  0.8 ± 0.1 
(10Fe)PHD2(50Ni)  1.7 ± 0.1         1.7 ± 0.1  1.0 ± 0.1          
(10Fe)PHD2(50Mn)  1.7 ± 0.1          1.7 ± 0.2 1.0 ± 0.1 
(10Fe)PHD2(50Zn)  1.4 ± 0.1          0.8 ± 0.1 1.7 ± 0.2     
(10Fe)PHD2(50Co)  1.6 ± 0.1 0.5 ± 0.1  3.4 ± 0.2 
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4.3.3 XAS shows that Zn2+ binds to the allosteric site on WT-PHD2 
The allosteric metal binding site was happen to be centered with Cys201 by 
mutagenesis.  We wished to define the metical  parameters of this site using EXAFS.  X-
ray absorption spectroscopy shows that Zn2+ binds to the allosteric site of PHD2, 
adopting a six coordinate geometry, two cysteine (Cys201 and Cys208), one Tyr197, His205 
and two water ligand.  In the case of Cys201àAla, Zn2+ bound to the active site, which 
was  replacing the Fe3+.  In aerobic samples of WT-PHD2 and Cys201àAla with Fe3+ and 
Ni2+, Ni2+ expelled the Fe3+ from the active site and bound to the active site. 
 
 
 
Figure 4.7 K-edge XAS spectra of WT-PHD2 with Zn(II) (Done by Carolyn Carr) 
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Figure 4.8 K-edge XAS spectra of Cys201àAla with Zn2+ (Done by Carolyn Carr)
Table 4.2 Selected EXAFS fits for WT-PHD2 and Cys201àAla with Zn2+ and Fe3+ 
(Done by Carolyn Carr) 
 
Sample CN Shell r (Å) σ2 (x10-3 Å-2) ΔEo (eV) %R 
WT Zn(II) 6 3N/O 2.07(2) 2.6(1.8) 2.9(0.9) 0.57 
  (1Imd)     
  (1Tyr)     
  2S 2.32(1) 5.5(1.0)   
  1Br 2.39(2) 12.8(3.3)   
C201A Zn(II) 6 4N/O 2.10(1) 2.3(0.6) 1.4(0.8) 1.6 
  (2Imd)     
  1N/O 2.22(1) 3.89(0.7)   
  1Br 2.44(2) 12.7(2.1)   
  (1Imd) 2.07(2) 2.6(1.8) 2.9(0.9) 0.57 
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4.4 Discussion 
There was a conflict about how certain transition metals such as, Zn2+, Ni2+, Co2+, 
Cu2+, and Mn2+ induce hypoxic response and stabilize HIF-1α.  The most likely reason is 
due to the inhibition of PHD2, which is responsible in regulating HIF-1α level in the 
cells.  Two possible way of PHD2 inhibition by these metals has been proposed 
previously.  First one is these transition metals simply replace the Fe2+ from the active 
site which requires tighter binding of these metals than Fe2+ to enzyme active site. 
Second one, these transition metals bind to different place on enzyme rather that the 
active site and allostericly inhibits the PHD2.   
Our addition of order experiments revealed that Zn2+, Cu2+, Mn2+ and Co2+ 
preferably binds to the active site instead of Fe2+ under competitive conditions. Except 
with the Ni2+, which showed only 25 % inhibition which suggest that active site has 
higher preference for Fe2+ than Ni2+.  Under noncompetitive conditions where the enzyme 
pre-incubated with Fe2+ then the second metal was added, enzyme showed a different 
inhibition profile in case of Zn2+, Mn2+, and Co2+ these metals inhibited the enzyme by 
only 40 % suggesting that these metals are not replacing the Fe2+ instead inhibiting the 
enzyme a different way, possibly allostericly.  Exception with the Cu2+ which completely 
inhibited enzyme like competitive conditions, by binding to enzyme active site and Ni2+ 
also inhibited the enzyme by 25 % similar inhibition profile with competitive conditions. 
Since there has been a report showing that PHD2 can bind more that one metal 
such as Zn2+, Co2+ and Cu2+ and mutation of either of Cys201àAla and Cys208àAla 
prevented binging of two metal and only one metal binds to these mutants indicated that 
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these metals binding to these Cys201Cys208 site (scoff).  We performed Cys201àAla 
mutation to investigate how is the inhibition profile would be when we removed the 
second metal binding site.  Our competitive and noncompetitive activity measurements 
with these metals had the similar inhibition profile with WT-PHD2, which suggest that 
either these metals can still bind to the Cys201Cys208 site even though we removed one 
ligand or this second site is not effecting the enzyme activity. 
Our XAS experiments indicated that Zn2+ binds to the Cys201Cys208 allosteric site 
in aerobic samples with six coordinate, Cys201, Cys208, Tyr197, His205, and two water 
ligands.  Based on the crystal structure His205 residue appears to be bit far, this indicates 
that in order for Zn2+ bind PHD2 goes to conformational change.  Aerobic Cys201àAla 
Zn2+ sample seems like binds to the active site rather than the allosteric site, one possible 
reason for this is Zn2+ can replace the Fe3+ from the active site when Cys201 ligand is 
removed or during the chelex treatment chelex might have pull out the Fe3+ from the 
active site. 
Involvement of HIF-1α on disease such as angiogenesis, erythropoiesis, tumor 
growth, and etc. makes the PHD2 a potential drug target for hypoxia related diseases.  
Problem with the targeting the enzyme active site cause problems, biggest problem is 
same family of enzymes share common active site and it makes it difficult to come out 
with highly specific compound.  Therefore, it is more convenient to control the enzyme 
activity away from the active site to obtain greater selectivity.  This research is valuable 
to showing that it is possible to control the PHD2 activity away from the active site. 
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CHAPTER V 
SECOND COORDINATION SPHERE CONTROLS HIF-1α HYDROXYLATION 
5.1 Introduction 
HIF prolyl hydroxylase (PHD2) is a human O2 sensor. It is a non-heme Fe2+ 2-
oxoglutarate (2OG) dependent dioxygenase, which controls the level of hypoxia 
inducible factor-1α (HIF-1α) in cells1–3.  HIF-1α is a transcription factor, which trans-
activates the expression of over 100 genes such as angiogenesis, erythropoiesis, tumor 
growth, and etc., so its abundance in the body is important4–7.  PHD2 controls HIF-1α 
level by hydroxylating two specific proline residues in the ODD domain of HIF-1α, 
Pro402 and Pro564 1,8–10.  Hydroxylation of one or both proline residues is enough for HIF-
1α to be recognized by pVHL, a part of E3 ubiqutin ligase, which targets HIF-1α for 
proteasomal degradation1,11–13.  The role of PHD2 in controlling HIF-1α level makes it 
essential to understand how these enzyme work and which residues are essential for its 
hydroxylating function. 
 PHD2’s Fe2+ active site is six coordinate with a two histidine (His313 and His374) one 
aspartate (Asp315) facial triad (2His1Asp), co-substrate 2OG bound in a bidentate manner 
and a water ligand, these ligands are called first coordination sphere.  PHD2 follows a 
sequential ordered binding mechanism.  First substrate ODD binds and displaces a water 
ligand which opens up a coordination for O2 binding, O2 binds to this open coordination 
site upon O2 activation, co-substrate 2OG gets decarboxylated and the substrate gets 
hydroxylated14–18 (scheme 5.1).  The first coordination sphere residues are significant for 
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enzymatic reactivity but also the second coordination sphere residues may also play an 
important role. 
 
Scheme 5.1 Proposed chemical mechanism for PHD2 
 Crystal structures of PHD219 indicates that PHD2 has an extended hydrogen bonding 
network with second coordination sphere residues, which possibly play an important role 
in enzyme activity.  Residue Thr325 is involved in an hydrogen bonding with the facial 
triad Asp315 residue.  This hydrogen bonding might be important for proper positioning of 
Asp315, in order for chemistry to occur.  Here we tested the role of Thr325 residue in 
positioning the Asp315, facial triad residue by performing point mutations, steady state 
kinetic experiments and UV-Vis spectroscopy.   
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Our results revealed that Thr325 residue plays an important role in enzyme 
activity.  Thr325àAla mutation was 5 times less reactive in hydroxylating CODD 
substrate compared to WT-PHD2.  We also replaced the Asp315 ligand with glutamate, 
which is very similar to aspartate only one carbon bond longer.  The Asp315àGlu mutant 
had the same activity with WT-PHD2 and Asp315àAla mutation was very slow 
compared to wild type enzyme but it still hydroxylated CODD peptide.  The same 
mutations in other 2OG dependent dioxygenase, FIH, was reported to inhibit the 
enzyme20 unlike PHD2.  Reactivity of Asp315àAla mutant hydroxylating CODD shows 
that Fe2+ can still bind to the active site with two histidine ligands.  This research shows 
that there is more flexibility of in the Fe2+ coordination environment than other 2OG 
dependent dioxygenases. 
 
Figure 5.1 Active site of PHD2 showing the 2His1Asp facial triad, 2OG and Thr325 
residue. PDB ID: 3OUJ, distances (Å) and Water (red sphere). 
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5.2 Materials and methods 
5.2.1 Materials 
All the chemicals were purchased from chemical vendors, and used without 
further purification.  20 residue CODD substrate peptide (99 % purity) was purchased 
from GL Biochem LTD (Shanghai). The primers used were: Thr325àAla, forward, 5’	  –CCA	  AAT	  GGA	  GAT	  GGA	  AGA	  TGT	  GTG	  GCA	  TGT	  ATA	  TAT	  TAT	  CTT	  AAT	  AAA	  GA-­‐3’;	  reverse,	  5’-­‐	  TCT	  TTA	  TTA	  AGA	  TAA	  TAT	  ATA	  CAT	  GCC	  ACA	  CAT	  CTT	  CCA	  TCT	  CCA	  TTT	  GG	  -­‐3’;	  Asp315àAla, forward,	  5’-­‐	  GGG	  TTA	  TGT	  ACG	  TCA	  TGT	  TGC	  TAA	  TCC	  AAA	  –	   3’;	   reverse,	   5’-­‐	   TTC	   CAT	   CTC	   CAT	   TTG	   GAT	   TAG	   CAA	   CAT	   GAC-­‐3’;	  Asp315àGlu, 
forward, 5’- GTT ATG TAC GTC ATG TTG AGA ATC CAA ATG-3’; reverse,	  5’-­‐	  TTC	  CAT	  CTC	  CAT	  TTG	  GAT	  TCT	  CAA	  CAT	  GAC-­‐3’.	   	   The	  primers	  were	  purchased	   from	  IDT.	  
5.2.2 Point mutations 
Point mutations were performed by using the protocole modified from the 
quickchange site-directed mutagenesis kit of Stratagene.  Mutation primers were 
designed for Asp315àAla, Asp315àGlu, and Thr325àAla mutants by using the 
quickchange primer design program of Stratagene.  At least 30 basepaire legth primers 
were used and the mutated base was at the center of the primer sequence.  Reactions 
prepared for the PCR are shown on table 5.1. 
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Table 5.1 PCR reaction conditions. 
Reagent Stock concentration Volume used Final amount 
ddH2O  84 µL  
10X reaction buffer  10 µL  
dNTP  1 µL  
MgSO4 100 mM 1 µL 1 mM 
Primer (Sense) 125 ng/µL 1 µL 125 ng 
Primer (Anti-sense) 125 ng/µL 1 µL 125 ng 
pGEX-4T 100 ng/µL 1µL 100 ng 
Vent polymerase  1 µL  
 
Table 5.2 The PCR program setting. 
Step Temperature (OC) Time 
Denaturing 95 50 seconds 
Denaturing 95 50 seconds 
Annealing 62-65 50 second 
Extension 72 7 minutes 
Extension 72 7 minutes 
Store 4  
Bold, 16 cycles performed. 
	   101	  
 The PCR reactions were loaded to 1% agarose gel to check the plasmid replication.  
After the PCR product was confirmed on the agarose gel, samples were treated with DpnI 
for 1 hour at 37 OC to remove parental plasmid from PCR products.  Then 5 µL of DpnI 
treated PCR products were transformed to XL-1 blue cells and plated onto Ampicillin LB 
agar plates.  Plates were incubated at 37 OC for overnight.  A single colony was picked 
and grown in 5 mL of LB media containing Ampicillin media at 37 OC for overnight.  A 
miniprep was performed to isolate the plasmid from the overnight culture.  To confirm 
the sequence of the plasmids, sequencing samples were prepared containing 50 ng of 
plasmid and one of the sequencing primer either primer #29 or primer#35 then sent for 
sequencing.  Plasmids with mutated sequence were then transformed into BL-21 DE3 
cells, using the same procedure for XL-1 blue cell transformation.  
5.2.3 Purification of WT-PHD2 and its mutants, Asp315àAla, Asp315àGlu, and 
Thr325àAla 
WT-PHD2 and its mutant variants were purified as previously described21,22.  In 
summary, WT-PHD2 and its mutants were expressed in E. coli BL-21 DE3 cells using a 
pGEX-4T-1 vector (stratagene) as N-terminally GST-tag fusion protein.  GST-PHD2 
fusion protein was purified using a GSTrap affinity column (GE Bioscience), then the 
GST tag cleaved by treating the sample with restriction grade thrombin at 1 unit/mg at 4 
OC for 16 hrs.  After 16 hours incubation with thrombin, the thrombin was removed using 
Hitrap Benzamidine column (GE Bioscience), then the GST tag removed by a GSTrap 
column.  Purity of enzymes were checked with 10 % SDS page and the masses were 
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confirmed by QStarTOF mass spectrometer.  Purified WT-PHD2 and its variants were 
then buffer exchanged with 50 mM HEPES pH 7.5 and storred at -20 OC. 
5.2.4 Steady state kinetic assays 
Steady state kinetic assays were performed under saturating concentrations of  
(NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), CODD (10-20 µM), ascorbic acid (1 mM), and 
enzyme (1-2 µM).  Initial rates were determined by directly measuring the hydroxylation 
of CODD peptide by Bruker Daltinics Omniflex MALDI-TOF mass spectrometer.  Initial 
rates (v0) were obtained from the change in mol fraction of hydroxylated CODDOH 2 
(cODDOH), as v0 = [CODD]0 cODDOH /t. 
5.2.5 Buffer preparation to obtain pH profile 
A three component buffers was prepared for pH range from 6.00 to 7.50 using 20 
mM HEPES, 20 mM MES, and 20 mM PIPES.  For pH 8.00 60 mM HEPES buffer was 
prepared and for pH 8.5 to pH 10.00 60 mM CHES buffers were prepared.  Reactions 
were performed with each pH. The pH of the reaction was also measured using a micro 
pH meter. 
5.2.6 Steady state kinetics for determining KM(O2) 
The initial rate measurements were performed under saturating concentrations of 
Fe2+ (10 µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37 
oC. O2 concentration was varied by continuously flowing the N2 and O2 gas at different 
ratios through a bag, then O2 concentration monitored by YSI model 5300 biological 
oxygen monitor.  Reactions were quenched at different time points in matrix solution, 
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saturated 4-α-cyano hydroxycinnamic acid (in 75 % acetonitrile and 0.2 %TFA).  
Samples were then spotted onto a target plate and analyzed by a Bruker Daltonics 
Omniflex MALDI-TOF mass spectrometer.   
5.2.7 UV-Vis spectroscopy 
Anearobic samples of WT-PHD2, its variants, 2OG, Fe2+, 50 mM HEPES pH 7.00 
were prepared by flushing argon gas through the samples for 30 minutes.  The samples 
were then taken into a glove box in which the UV-Vis samples were prepared.  Samples 
contained WT-PHD2 or its mutant (600 µM), 2OG (600 µM), and Fe2+ (550 µM) in 50 
mM HEPES pH 7.00 buffer containing 150 mM NaCl .  Apo WT-PHD2 and apo mutant 
spectrum also obtained and used as background spectrum. 
5.3 Results 
5.3.1 Thr325àAla plays a key role in hydroxylating the CODD substrate peptide 
The initial rates of turnover were measured as a function of varied CODD or 
2OG, and the rate constants, KM and kcat/KM were obtained by fitting the data to a 
Micheles-menten equation (equation 5.1). Steady state kinetic assays showed that 
KM(CODD) and KM(2OG) were similar to the wild type PHD2 for all the mutants (Table 5.3) 
while kcat/KM were different for Thr325àAla and Asp315àAla.  Thr325àAla form of the 
PHD2 had 5 times less reactivity for hydroxylating CODD than WT-PHD2.  Since the 
Asp315 is one of the active site facial triad residues, breaking it drastically inhibited the 
enzyme.  The Asp315àGlu mutant had similar activity with WT-PHD2, which was 
interesting because previously, a similar mutation to an enzyme of the same class of 
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enzymes had been reported to inhibit that enzyme but for PHD2 this small alteration in 
the active site residue did not change its activity.   
 
Figure 5.2 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2, Asp315àAla, 
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are 
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.  
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10 µM), 
ascorbic acid (1 mM), 2OG (100 µM), and CODD (2-20 µM) in 50 mM HEPES pH 7.00, 
37°C, ambient [O2](217 µM). 
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Figure 5.3 Determination of kinetic constants kcat/KM(2OG) for WT-PHD2 and, 
Asp315àAla, Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open 
triangles are Asp315àAla, closed triangles are Asp315àGlu, and open circles are 
Thr325àAla.  Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), 
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (1-50 µM), and CODD (20 µM) in 
50 mM HEPES pH 7.00, 37°C, ambient [O2](217 µM). 	  
Table 5.3 Steady state kinetic parameters of WT-HD2 and mutants for CODD and 2OG.  
Enzyme kcat, min-1  kcat/KM, min-1 
µM-1 
KM(CODD), µM KM(2OG), µM 
WT-PHD2 2.7 ± 0.1 3.9 ± 0.5 0.7 ± 0.1 1.2 ± 0.2 
Thr325àAla 0.4 ± 0.1 0.2 ± 0.1 1.5 ± 0.2 1.6 ± 0.3 
Asp315àAla 0.04 ± 0.01 0.6 ± 0.1 0.1< 0.06 ± 0.03 
Asp315àGlu 2.1 ± 0.1 3.0 ± 0.4 0.7 ± 0.1 3.3 ± 0.4 
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5.3.2 Mutations did not alter the protonation state of PHD2 
PHD2 activity as previously reported is highly pH dependent.  The pKa of WT-
PHD2 and its mutants were determined by measuring the initial rate turnover of substrate 
CODD in the pH range of 6-9.5.  All the initial rate measurements were performed under 
saturating concentrations of (NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), ascorbic acid (1 
mM), CODD (20 µM), and WT-PHD2 (1 µM) or mutant (2-10 µM) in an air saturated 
HMP (HEPES + MES + PIPES) or CHES buffer at 37°C.  The initial rates of turnover 
were measured as a function of varied [CODD].  pKas were determined for WT-PHD2 
and its mutants by fitting the data to equation 5.2. The rate of turnover for WT-PHD2 was 
pH dependent as previously reported.  At pH 6.75, WT-PHD2 had its highest activity, 
which indicates the PHD2 has an active site acid and upon deprotonation , the enzyme 
showed lower activity.  All of the mutants also showed similar pH dependence and they 
had very similar pKas (Table 5.4) suggesting that none of these mutated residues are the 
cause of PHD2’s pH dependence.  
Equation 5.3 𝑓 𝑠 =   𝑘!!"# +   !!"#$  !!!"#$  !!!"(!"!!!)  
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Figure 5.4 pKa of WT-PHD2 and its mutants.  Closed squares are WT-PHD2, open 
triangles are Asp315àAla, closed triangles are Asp315àGlu, and open circles are 
Thr325àAla.  Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), 
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in 
HMP (HEPES + MES + PIPES) or CHES buffer at ambient [O2], 37 °C. 
 
Table 5.4 pKa of WT-PHD2 and its mutants. 
Enzyme pKa 
WT-PHD2 7.6 ± 0.1 
Thr325àAla 7.9 ± 0.1 
Asp315àAla 7.5 ± 0.1 
Asp315àGlu 7.5 ± 0.2 
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5.3.3 WT-PHD2 and mutants have similar KM(O2) exception the Asp315àGlu mutant 
which showed inhibition at high [O2] 
The initial rates of WT-PHD2, Asp315àAla, Asp315àGlu, and Thr325àAla were 
measured at a varied O2 concentrations using the saturating concentrations of Fe2+ (10 
µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37 °C. WT-
PHD2 and mutants showed simple saturation kinetics over the range of 6 µM to 1 mM O2 
concentration except Asp315àGlu which showed inhibition at higher than 600 µM [O2], 
(Figure 5.5).  The steady state kinetic parameters of the mutants were similar to that of 
WT-PHD2 (Table 5.5) with the exception of Asp315àGlu which had a lower KM(O2), than 
WT-PHD2, 207 µM and 576 µM respectively (Table 5.5).  These results indicate that 
Thr325 and Asp315 do not play a role in the affinity of the enzyme for O2. 
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Figure 5.5 Determination of kinetic constants kcat/KM(O2) for WT-PHD2, Asp315àAla, 
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are 
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.  
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10 µM), 
ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in 50 mM HEPES pH 7.00, 
37 °C. 
 
Table 5.5 Steady state kinetic parameters of WT-PHD2 and mutants for O2. 
Enzyme kcat/KM(O2), min-1 µM-1 KM(O2), µM 
WT-PHD2 0.02 ± 0.01 527 ± 92 
Thr325àAla 0.003 ± 0.001 486 ± 171 
Asp315àAla 0.01< 576 ± 124 
Asp315àGlu 0.02 ± 0.01 207 ± 45 
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5.3.4 Electron density around the Fe2+ has been altered in Asp315àAla and 
Asp315àGlu mutants 
Previous reports with PHD2 and other dioxygenase such as FIH, taurine dioxygenase 
(TauD) showed that changes in the Fe2+ coordination environment lead to shifts in the 
UV-visible absorption spectra in the 300 - 600 nm range due to the metal to ligand charge 
transfer transitions (MLCT)16,17,21,23.  In this case the MLCT is between Fe2+ and 2OG co-
substrate.  UV-visible absorption spectra of anaerobic samples of (Fe2+ + 2OG + WT-
PHD2) and its mutant variants (Fe2+ + 2OG + Mutant) were recorded to monitor any 
possible changes to the Fe2+ coordination environment.  Apo WT-PHD2 and apo mutant 
spectrums were also obtained and used as background spectra.  MLCT region has 
changed in the Asp315àGlu and Asp315àAla mutants. As seen in figure 5.6, it shifted 
from 500 nm to 490 nm.   
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Figure 5.6 The UV-visible spectrum of WT-PHD2, Asp315àGlu, and Asp315àAla with 
Fe2+ 2OG. (Fe2+ + 2OG)WT-PHD2, (Fe2+ + 2OG)Asp315àGlu, and (Fe2+ + 2OG) 
Asp315àAla.  Black line is (Fe2+ + 2OG)WT-PHD2, sample includes 600 µM WT-
PHD2, 550 µM Fe2+ and 600 µM 2OG. Dark gray line is (Fe2+ + 2OG)Asp315àGlu, 
sample includes 600 µM Asp315àGlu, 550 µM Fe2+, and 600 µM 2OG.  Light gray line is 
(Fe2+ + 2OG)Asp315àAla, samples includes, 350 µM Asp315àGlu, 320 µM Fe2+, and 
350 µM 2OG in 50 mM HEPES 150 mM NaCl pH 7.00. 	  
5.4 Discussion 
Our steady state kinetic experiments indicated that second coordination sphere 
residue Thr325 is essential for positioning the Asp315 facial triad residue and breaking the 
hydrogen bonding between these two residues inhibited the enzyme by 80 %. 
Interestingly, the KM(CODD), KM(2OG), and KM(O2) are not altered by alanine (Table 5.3) 
suggesting that Thr325 is not involved in CODD, 2OG or O2 binding.  Previous reports 
showed that PHD2’s activity is highly pH dependent and the enzyme is more reactive in 
hydroxylatingg CODD at lower pH.  Our pH experiments results indicate that 
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Thr325àAla mutation did not altered the protonation state of PHD2 and Thr325 is not 
responsible for the pH dependence of PHD2.   
 
Facial triad residues (2His1Asp) are highly conserved among the non-heme Fe2+ 
dependent dioxygenases and removal of one of these ligands was reported to inhibit the 
enzymatic activity in other dioxygenases such as FIH.  We performed mutation of 
Asp315àAla and Asp315àGlu and tested the hydroxylation activity and our results 
revealed that Asp315àGlu mutation can hydroxylate the CODD peptide as effective as 
WT-PHD2 with the apparent kcat/KM of 3.0 and 3.9, respectively (Table 5.3).  The 
Asp315àAla mutant had very low reactivity for hydroxylating CODD.  Both mutants of 
Asp315 had similar pKa values to WT-PHD2, indicating that Asp315 does not play a role in 
pH dependence of PHD2.  Asp315àAla’s ability to hydroxylate CODD substrate peptide 
indicates that Fe2+ can bind to the active site even without one of the ligands or highly 
conserved 2His1Asp facial triad ligands. 
 
We also tested the O2 sensitivity of Asp315àAla and Asp315àGlu compared to the 
WT-PHD2.  Asp315àAla had a similar KM(O2) to WT-PHD2, 576 µM and 527 µM, 
respectively (Figure5.5), while Asp315àGlu mutant showed different kinetic behavior 
compared to WT-PHD2.  WT-PHD2 activity increased with increasing [O2] and had 
maximum activity higher than 800 µM whereas Asp315àGlu mutant’s activity increased 
with increasing [O2] concentration until 600 µM [O2] then activity started to drop at 
higher [O2] (Figure 5.5).  In some 2OG dependent dioxygenases such as FIH it has been 
reported that the enzyme can auto hydroxylate itself forming an inactive or less reactive 
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form of the enzyme.  The inhibition of Asp315àGlu with increasing [O2] suggest that 
Asp315àGlu might also be doing auto hydroxylation like FIH does which leads to partial 
enzyme inhibition at higher than 600 µM [O2]. 
 
The UV-visible spectroscopy showed that the electron density around the Fe2+ active 
site center of WT-PHD2 has changed with Asp315àGlu and Asp315àAla mutants.  The 
blue shift in MLCT band was observed with these mutations  (Figure 5.6).  For WT-
PHD2 and Thr325àAsn mutant MLCT bands appeared at 500 nm while for Asp315àGlu 
and Asp315àAla mutant, it appeared at 490 mM.  Similar shifts in MLCT bands have 
been previously reported for FIH23.  
 
 This study showed that Thr325 residue plays an important role in CODD hydroxylation 
by positioning the Asp315 residue for effective hydroxylation as removal of the interaction 
between these two residues causes partial enzyme inhibition.  The replacement of Asp315 
with alanine or glutamate do not prevent binding of Fe2+ to the active site based on 
activity assays but it binds more weakly to Asp315àAla as seen by UV-vis studies 
(Figure 5.6) and unlike some other non-heme Fe2+ 2OG dependent dioxygenases20 PHD2 
does not lose its ability to hydroxylate CODD substrate peptide. 
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CHAPTER VI 
FUTURE DIRECTIONS 
 
1. Today there is no intermediate observed for PHD2 but very interesting kinetic 
behavior of Thr387àAla mutant now can make it possible.  Our steady state kinetic 
studies with Thr387àAla mutation indicated that release of succinate is RDS and using 
Stopped-flow instrument it may be possible the monitor Fe(IV)-(Succinate) complex or 
even some other intermediates. 
 
2. Our results revealed that PHD2 has six coordinate Zn(II) binding site and its 
role in regulating PHD2 activity still needs to be studied.  Binding of two metal to PHD2 
in the case of Cu(II) and Co(II) was also reported previously, these metals are possibly 
binding to these Cys201Cys208 site and the effect of these metals on PHD2 activity need 
further study. 	  
3. According to a consensus chemical mechanism substrate binding to the active 
site happens prior to oxygen activation. Based on the crystal structure of PHD2 
containing a 17 residue fragment of the CODD, it is witnessed that the substrate induces a 
large conformational change in the structure of PHD2.  The loop region (β2β3) flips up 
and closes over the active site entrance (Figure 6.1).  
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Figure 6.1 A) PHD2 crystal structure without substrate (2G19). B) PHD2 crystal 
structure with the substrate (colored purple) (3HQR). (Both structures have the same 
orientation). 	  
Although there is no clear way for O2 to reach the active site there appears to be a 
convoluted channel. Residues, Gln239, Arg252, Trp258, Ile256, and Met299 residues of PHD2 
and Tyr565 residue in ODD line the front of the proposed oxygen channel (Figure 6.1). 
My model is if this cavity is necessary for O2 to enter the active site then the enzyme 
activity can be altered by changing the width of the channel.  If convoluted channel is O2 
channel then it might be possible to make the PHD2 active at lower [O2] by altering the 
size of these channel by point mutations. 	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Figure 6.2 A view of O2 channel, showing the residues line in front of the channel. 
Purple stick representation is CODD. 
	  
In order to test whether it is an O2 channel or not, point mutations of residues 
(Figure 6.2), Gln239àAla, Arg252àAla, Trp258àAla, Ile256àA, and Met299àAla in 
PHD2 and another mutation in CODD, Tyr565àAla which increase the size of this cavity 
can be performed. KM(O2) values for each mutant can be determined and compared to wild 
type enzyme. If this possible channel is necessary for O2 to enter the PHD2 active site, it 
is expected that those alanine mutations will increase the rate of O2 entering the active 
site, which will decrease the KM(O2).   It is possible that PHD2 can do the hydroxylation 
chemistry at lower [O2]. 
Crystallographic Studies of Xe binding experiment can be done to visualize the 
O2 channel. Xe binds to hydrophobic surface in the proteins Xe will pass from this O2 
channel and bind to the active site. The binding rate for each mutant expected to be 
higher than the wild type of the enzyme.  
The results gained from these experiments will be vitally important to control the O2 
access structurally. 
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APPENDIX A 
pGEX-4T-1 VECTOR (FROM GE HEALTHCARE) 	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APPENDIX B 
AMINO ACID SEQUENCE OF WT-PHD2178-426 THAT WAS USED IN THIS 
STUDY 	  
178G S R P N G Q T K P L P A L K L A L E Y I V P C M N K H G I C V V D D F L G 
K E T G Q Q I G D E V R A L H D T G K F T D G Q L V S Q K S D S S K D I R G D 
K I T W I E G K E P G C E T I G L L M S S M D D L I R H C N G K L G S Y K I N G 
R T K A M V A C Y P G N G T G Y V R H V D N P N G D G R C V T C I Y Y L N K 
D W D A K V S G G I L R I F P E G K A Q F A D I E P K F D R L L F F W S D R R N 
P H E V Q P A Y A T R Y A I T V W Y F D A D E R A R A K V K Y L T G E K G V R 
V E L N K P S D S V G K D V F426 
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APPENDIX C 
FORWARD AND REVERSE PRIMER SEQUENCES OF MUTANTS 	  
Thr387àAla, forward, 5’- CAT ATG CTA CAA GGT ACG CAA TAG CTG TTT -3’; 
reverse, 5’- GCA TCA AAA TAC CAA ACA GCT ATT GCG TA -3’. 
Thr387àAsn, forward, 5’- CCA	  GCA	  TAT	  GCT	  ACA	  AGG	  TAC	  GCA	  ATA	  AAT	  GTT	  TGG	  TAT	  TTT	  GAT	  -­‐3’;	  reverse,	  5’-­‐	  ATC	  AAA	  ATA	  CCA	  AAC	  ATT	  TAT	  TGC	  GTA	  CCT	  TGT	  AGC	  ATA	  TGC	  TGG	  -­‐3’.	  
Cys201àAla, forward, 5’- GCT	  CGA	  GTA	  CAT	  CGT	  GCC	  GGC	  CAT	  GAA	  CAA	  GCA	  C	  -­‐3’;	  reverse,	  5’-­‐	  GTG	  CTT	  GTT	  CAT	  GGC	  CGG	  CAC	  GAT	  GTA	  CTC	  GAG	  C	  -­‐3’. 
Thr325àAla, forward, 5’	  –CCA	  AAT	  GGA	  GAT	  GGA	  AGA	  TGT	  GTG	  GCA	  TGT	  ATA	  TAT	  TAT	  CTT	  AAT	  AAA	  GA	   -­‐3’;	   reverse,	  5’-­‐	  TCT	  TTA	  TTA	  AGA	  TAA	  TAT	  ATA	  CAT	  GCC	  ACA	  CAT	  CTT	  CCA	  TCT	  CCA	  TTT	  GG	  -­‐3’.	  
Asp315àAla, forward,	  5’-­‐	  GGG	  TTA	  TGT	  ACG	  TCA	  TGT	  TGC	  TAA	  TCC	  AAA	  -­‐3’;	  reverse,	  5’-­‐	  TTC	  CAT	  CTC	  CAT	  TTG	  GAT	  TAG	  CAA	  CAT	  GAC	  -­‐3’.	  
Asp315àGlu, forward, 5’- GTT ATG TAC GTC ATG TTG AGA ATC CAA ATG-3’; 
reverse,	  5’-­‐	  TTC	  CAT	  CTC	  CAT	  TTG	  GAT	  TCT	  CAA	  CAT	  GAC-­‐3’.	  Sequencing	   primers,	   forward	   (#29),	   5’-­‐	   CAT	   GGA	   CCC	   AAT	   GTG	   CCT	   GGA	   TG-­‐3’;	  reverse(#35),	  5’-­‐	  CTC	  CGC	  TAT	  CGC	  TAC	  GTG	  ACT	  G-­‐3’.	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